STOCK TITAN

Nexentis Technologies issues going-concern warning

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Nexentis Technologies Inc. (NXTS) reported a net loss of $12.730 million for the nine months ended September 30, 2026, versus $5.395 million a year earlier. Its continuing biotechnology and renewable-energy segments reported no revenue for the period; operating loss was $11.335 million, including a noncash $6.291 million goodwill impairment at MitoCareX.

Third-quarter net gain was $5.019 million, compared with $370,000 a year earlier, while operating loss was $1.234 million. Financing income was $7.067 million for the quarter, versus $174,000 a year earlier. Nine-month operating cash outflow was $3.186 million, compared with $2.311 million.

At September 30, cash and equivalents were $2.837 million and short-term bank deposits were $3.324 million. Management said existing cash would not fund operations for the 12 months following issuance, creating substantial doubt about the company’s ability to continue as a going concern. It plans to seek equity financing or strategic-partnership capital, which may not be available. The Save Foods sale generated an $898,000 gain on deconsolidation.

2 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointThird-quarter net gain was $5.019 million, versus $370,000 a year earlier.
  • Minor pointSave Foods deconsolidation produced a $898,000 gain.

Negative

  • Major pointNine-month net loss widened to $12.730 million from $5.395 million.
  • Major point. Forward-looking: it has not happened yet and may not happen.Management projects existing cash will not fund operations for the next 12 months.
  • Moderate pointOperating cash outflow reached $3.186 million, versus $2.311 million.
  • Minor pointMitoCareX goodwill impairment was $6.291 million.

Filing Explained

The October twenty-six consulting-share issuance reduced existing holders’ percentage ownership, absent offsetting changes.

The filing reports that Nexentis completed a one-for-five reverse split on November 9, 2026: every five common shares became one, while the authorized common-share count remained 495 million. It reported 666,660 common shares outstanding as of November 16, 2026.

Separately, a lender exercised part of its warrants on October 7, 2026, and the company received approximately $552,000 in cash. On October 26, 2026, the company issued 2,000 common shares for consulting services and introductions to potential investors. That issuance increases the share count and reduces existing holders’ percentage ownership, absent offsetting changes.

Net loss $12.730 million Nine months ended September 30, 2026; compared with $5.395 million in 2025.
Operating loss $11.335 million Nine months ended September 30, 2026.
Net gain $5.019 million Three months ended September 30, 2026; compared with $370,000 in 2025.
Net cash used in operating activities $3.186 million Nine months ended September 30, 2026; compared with $2.311 million in 2025.
Goodwill impairment $6.291 million Noncash impairment for the MitoCareX reporting unit, recognized during the nine months ended September 30, 2026.
Cash and cash equivalents $2.837 million As of September 30, 2026.
Gain on deconsolidation $898,000 Save Foods sale; recognized during the nine months ended September 30, 2026.
Voice Assist investment fair value Approximately $397,000 As of September 30, 2026; the company recognized an approximately $795,000 fair-value loss during the nine months.
substantial doubt financial
"substantial doubt regarding the Company’s ability to continue as a going concern"
goodwill impairment financial
"non-cash goodwill impairment loss of $6.3 million"
Goodwill impairment occurs when a company’s valued reputation or brand strength, known as goodwill, is found to be worth less than previously recorded on its financial statements. This usually happens when the company's performance declines or market conditions change, signaling that the expected benefits from acquisitions or brand value are no longer as strong. It matters to investors because it can indicate that a company's assets are less valuable than initially thought, potentially affecting its overall financial health.
discontinued operations financial
"Net gain (loss) from discontinued operations"
Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.
fair value option financial
"elected to account for the loans under the fair value option"
An accounting election that lets a company measure eligible financial assets and liabilities at their current market price, recording gains and losses in the income statement as those prices move. For investors it matters because choosing the fair value option makes reported profits and asset values respond immediately to market swings—like revaluing a house to today’s sale price—so it can increase earnings volatility while giving a more up‑to‑date view of value.
Level 3 technical
"categorized as Level 3 within the fair value hierarchy"
Level 3 describes the lowest-confidence category in the accounting “fair value” hierarchy, covering assets or liabilities whose prices are not observable in the market and must be estimated using judgment and internal models. For investors, Level 3 items matter because they can introduce greater uncertainty and potential valuation swings—like valuing a unique antique versus checking a price tag on a supermarket shelf—so they signal higher model risk and lower liquidity.
contingent consideration financial
"The Contingent share consideration was calculated as of September 30, 2026"
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did NXTS lose in the first nine months of 2026?

Nexentis reported a consolidated net loss of $12.730 million for the nine months ended September 30, 2026, compared with $5.395 million for the same period in 2025. Net cash used in operating activities was $3.186 million.

What were NXTS's third-quarter 2026 net gain and operating loss?

Nexentis reported a net gain of $5.019 million and an operating loss of $1.234 million for the three months ended September 30, 2026. Financing income was $7.067 million for that quarter.

What does NXTS say about its ability to fund operations?

Management said existing cash would not be sufficient to fund operations during the 12 months following issuance, creating substantial doubt about Nexentis's ability to continue as a going concern. It plans to seek financing through additional equity securities or strategic-partnership capital, which may not be available on favorable terms or at all.

How much goodwill did NXTS impair, and which business was affected?

Nexentis recognized a noncash goodwill impairment loss of $6.291 million for the MitoCareX reporting unit during the nine months ended September 30, 2026. Its interim quantitative impairment assessment was performed as of March 31, 2026.

What did NXTS receive in the Save Foods sale?

Nexentis received 60,198,540 shares of Voice Assist common stock as consideration. The shares were valued at approximately $1.192 million at closing; their fair value was approximately $397,000 at September 30, 2026, and Nexentis recognized an approximately $795,000 loss from changes in fair value during the nine months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 Q3 0001789192 0001789192 2026-01-01 2026-09-30 0001789192 2026-11-16 0001789192 2026-09-30 0001789192 2025-12-31 0001789192 2026-04-01 2026-04-30 0001789192 us-gaap:SubsequentEventMember 2026-11-01 2026-11-30 0001789192 2025-01-01 2025-09-30 0001789192 2026-07-01 2026-09-30 0001789192 2025-07-01 2025-09-30 0001789192 us-gaap:CommonStockMember 2025-12-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2025-12-31 0001789192 us-gaap:RetainedEarningsMember 2025-12-31 0001789192 us-gaap:ParentMember 2025-12-31 0001789192 us-gaap:NoncontrollingInterestMember 2025-12-31 0001789192 us-gaap:CommonStockMember 2026-03-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2026-03-31 0001789192 us-gaap:RetainedEarningsMember 2026-03-31 0001789192 us-gaap:ParentMember 2026-03-31 0001789192 us-gaap:NoncontrollingInterestMember 2026-03-31 0001789192 2026-03-31 0001789192 us-gaap:CommonStockMember 2026-06-30 0001789192 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2026-06-30 0001789192 us-gaap:RetainedEarningsMember 2026-06-30 0001789192 us-gaap:ParentMember 2026-06-30 0001789192 us-gaap:NoncontrollingInterestMember 2026-06-30 0001789192 2026-06-30 0001789192 us-gaap:CommonStockMember 2024-12-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2024-12-31 0001789192 us-gaap:RetainedEarningsMember 2024-12-31 0001789192 us-gaap:ParentMember 2024-12-31 0001789192 us-gaap:NoncontrollingInterestMember 2024-12-31 0001789192 2024-12-31 0001789192 us-gaap:CommonStockMember 2025-03-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2025-03-31 0001789192 us-gaap:RetainedEarningsMember 2025-03-31 0001789192 us-gaap:ParentMember 2025-03-31 0001789192 us-gaap:NoncontrollingInterestMember 2025-03-31 0001789192 2025-03-31 0001789192 us-gaap:CommonStockMember 2025-06-30 0001789192 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2025-06-30 0001789192 us-gaap:RetainedEarningsMember 2025-06-30 0001789192 us-gaap:ParentMember 2025-06-30 0001789192 us-gaap:NoncontrollingInterestMember 2025-06-30 0001789192 2025-06-30 0001789192 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2026-01-01 2026-03-31 0001789192 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001789192 us-gaap:ParentMember 2026-01-01 2026-03-31 0001789192 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0001789192 2026-01-01 2026-03-31 0001789192 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001789192 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2026-04-01 2026-06-30 0001789192 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001789192 us-gaap:ParentMember 2026-04-01 2026-06-30 0001789192 us-gaap:NoncontrollingInterestMember 2026-04-01 2026-06-30 0001789192 2026-04-01 2026-06-30 0001789192 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001789192 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2026-07-01 2026-09-30 0001789192 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001789192 us-gaap:ParentMember 2026-07-01 2026-09-30 0001789192 us-gaap:NoncontrollingInterestMember 2026-07-01 2026-09-30 0001789192 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2025-01-01 2025-03-31 0001789192 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001789192 us-gaap:ParentMember 2025-01-01 2025-03-31 0001789192 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001789192 2025-01-01 2025-03-31 0001789192 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001789192 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2025-04-01 2025-06-30 0001789192 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001789192 us-gaap:ParentMember 2025-04-01 2025-06-30 0001789192 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001789192 2025-04-01 2025-06-30 0001789192 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001789192 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2025-07-01 2025-09-30 0001789192 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001789192 us-gaap:ParentMember 2025-07-01 2025-09-30 0001789192 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0001789192 us-gaap:CommonStockMember 2026-09-30 0001789192 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2026-09-30 0001789192 us-gaap:RetainedEarningsMember 2026-09-30 0001789192 us-gaap:ParentMember 2026-09-30 0001789192 us-gaap:NoncontrollingInterestMember 2026-09-30 0001789192 us-gaap:CommonStockMember 2025-09-30 0001789192 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001789192 NXTS:ForeignCurrencyTranslationAdjustmentsMember 2025-09-30 0001789192 us-gaap:RetainedEarningsMember 2025-09-30 0001789192 us-gaap:ParentMember 2025-09-30 0001789192 us-gaap:NoncontrollingInterestMember 2025-09-30 0001789192 2025-09-30 0001789192 NXTS:SaveFoodsLtdMember 2009-04-27 0001789192 NXTS:SaveFoodsLtdMember 2026-03-15 0001789192 NXTS:SaveFoodsLtdMember NXTS:SecuritiesExchangeAgreementMember 2026-03-15 0001789192 us-gaap:FairValueInputsLevel1Member NXTS:InvestmentInSolterraMember 2026-09-30 0001789192 us-gaap:FairValueInputsLevel2Member NXTS:InvestmentInSolterraMember 2026-09-30 0001789192 us-gaap:FairValueInputsLevel3Member NXTS:InvestmentInSolterraMember 2026-09-30 0001789192 NXTS:InvestmentInSolterraMember 2026-09-30 0001789192 us-gaap:FairValueInputsLevel1Member NXTS:InvestmentInVoiceAssistMember 2026-09-30 0001789192 us-gaap:FairValueInputsLevel2Member NXTS:InvestmentInVoiceAssistMember 2026-09-30 0001789192 us-gaap:FairValueInputsLevel3Member NXTS:InvestmentInVoiceAssistMember 2026-09-30 0001789192 NXTS:InvestmentInVoiceAssistMember 2026-09-30 0001789192 us-gaap:FairValueInputsLevel1Member NXTS:SolarPvJointVentureProjectMember 2026-09-30 0001789192 us-gaap:FairValueInputsLevel2Member NXTS:SolarPvJointVentureProjectMember 2026-09-30 0001789192 us-gaap:FairValueInputsLevel3Member NXTS:SolarPvJointVentureProjectMember 2026-09-30 0001789192 NXTS:SolarPvJointVentureProjectMember 2026-09-30 0001789192 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001789192 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001789192 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001789192 us-gaap:FairValueInputsLevel1Member NXTS:InvestmentInSolterraMember 2025-12-31 0001789192 us-gaap:FairValueInputsLevel2Member NXTS:InvestmentInSolterraMember 2025-12-31 0001789192 us-gaap:FairValueInputsLevel3Member NXTS:InvestmentInSolterraMember 2025-12-31 0001789192 NXTS:InvestmentInSolterraMember 2025-12-31 0001789192 us-gaap:FairValueInputsLevel1Member NXTS:SolarPvJointVentureProjectMember 2025-12-31 0001789192 us-gaap:FairValueInputsLevel2Member NXTS:SolarPvJointVentureProjectMember 2025-12-31 0001789192 us-gaap:FairValueInputsLevel3Member NXTS:SolarPvJointVentureProjectMember 2025-12-31 0001789192 NXTS:SolarPvJointVentureProjectMember 2025-12-31 0001789192 us-gaap:FairValueInputsLevel1Member NXTS:ConvertibleLoansToSolterraMember 2025-12-31 0001789192 us-gaap:FairValueInputsLevel2Member NXTS:ConvertibleLoansToSolterraMember 2025-12-31 0001789192 us-gaap:FairValueInputsLevel3Member NXTS:ConvertibleLoansToSolterraMember 2025-12-31 0001789192 NXTS:ConvertibleLoansToSolterraMember 2025-12-31 0001789192 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001789192 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001789192 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001789192 NXTS:SolarPhotovoltaicJointVentureProjectMember 2025-12-31 0001789192 NXTS:ConvertibleLoanToSolterraMember 2025-12-31 0001789192 NXTS:SolarPhotovoltaicJointVentureProjectMember 2026-01-01 2026-09-30 0001789192 NXTS:ConvertibleLoanToSolterraMember 2026-01-01 2026-09-30 0001789192 NXTS:SolarPhotovoltaicJointVentureProjectMember 2026-09-30 0001789192 NXTS:ConvertibleLoanToSolterraMember 2026-09-30 0001789192 NXTS:StockPurchaseWarrantsLiabilityMember 2025-12-31 0001789192 NXTS:WarrantLliabilitiesToPureCapitalMember 2025-12-31 0001789192 NXTS:CreditFacilityMember 2025-12-31 0001789192 NXTS:ContingentConsiderationMember 2025-12-31 0001789192 NXTS:StockPurchaseWarrantsLiabilityMember 2026-01-01 2026-09-30 0001789192 NXTS:WarrantLliabilitiesToPureCapitalMember 2026-01-01 2026-09-30 0001789192 NXTS:CreditFacilityMember 2026-01-01 2026-09-30 0001789192 NXTS:ContingentConsiderationMember 2026-01-01 2026-09-30 0001789192 NXTS:StockPurchaseWarrantsLiabilityMember 2026-09-30 0001789192 NXTS:WarrantLliabilitiesToPureCapitalMember 2026-09-30 0001789192 NXTS:CreditFacilityMember 2026-09-30 0001789192 NXTS:ContingentConsiderationMember 2026-09-30 0001789192 NXTS:MitoCareXBioLtdMember 2025-10-20 0001789192 NXTS:MitoCareXBioLtdMember 2025-10-20 2025-10-20 0001789192 NXTS:MitoCareXBioLtdMember 2026-01-01 2026-09-30 0001789192 NXTS:MitoCareXBioLtdMember NXTS:CiroLeonardoPierriMember 2025-10-20 2025-10-20 0001789192 srt:MaximumMember NXTS:CiroLeonardoPierriMember 2025-10-20 0001789192 srt:MaximumMember NXTS:CiroLeonardoPierriMember 2026-09-30 0001789192 NXTS:LoanAgreementMember NXTS:SolterraRenewableEnergyLtdMember 2024-06-30 0001789192 NXTS:LoanAgreementMember NXTS:SolterraRenewableEnergyLtdMember 2024-06-30 2024-06-30 0001789192 NXTS:LoanAgreementMember NXTS:SolterraRenewableEnergyLtdMember 2024-01-01 2024-09-30 0001789192 NXTS:LoanAgreementMember NXTS:SolterraRenewableEnergyLtdMember 2026-07-31 0001789192 NXTS:LoanAgreementMember NXTS:SolterraRenewableEnergyLtdMember 2026-09-30 0001789192 NXTS:SolterraEnergyLtdMember 2024-01-01 2024-12-31 0001789192 NXTS:LoanAndPartnershipAgreementMember 2024-07-31 0001789192 NXTS:LoanAndPartnershipAgreementMember 2024-07-31 2024-07-31 0001789192 NXTS:LoanAndPartnershipAgreementMember 2025-12-31 0001789192 NXTS:LoanAndPartnershipAgreementMember 2025-12-24 0001789192 NXTS:NewLendersLoanAgreementMember 2025-12-24 0001789192 NXTS:NewLendersLoanAgreementMember 2026-06-04 0001789192 srt:MaximumMember 2026-06-04 2026-06-04 0001789192 srt:MinimumMember 2026-06-04 2026-06-04 0001789192 NXTS:LoanAndPartnershipAgreementMember 2026-09-30 0001789192 NXTS:LoanAgreementMember 2025-05-06 0001789192 NXTS:LoanAgreementMember 2025-05-06 2025-05-06 0001789192 NXTS:LoanAgreementMember 2026-09-30 0001789192 NXTS:SaveFoodsLtdMember 2026-01-13 0001789192 NXTS:SaveFoodsLtdMember 2026-03-15 2026-03-15 0001789192 NXTS:VoiceAssistMember us-gaap:CommonStockMember 2026-03-15 2026-03-15 0001789192 NXTS:VoiceAssistMember 2026-03-15 2026-03-15 0001789192 NXTS:VoiceAssistMember 2026-09-30 0001789192 NXTS:SaveFoodsIncMember 2026-03-15 2026-03-15 0001789192 NXTS:SaveFoodsLtdMember 2026-01-01 2026-09-30 0001789192 NXTS:SaveFoodsLtdMember 2025-01-01 2025-09-30 0001789192 NXTS:SaveFoodsLtdMember 2026-07-01 2026-09-30 0001789192 NXTS:SaveFoodsLtdMember 2025-07-01 2025-09-30 0001789192 2026-03-15 0001789192 2026-03-15 2026-03-15 0001789192 NXTS:FacilityAgreementMember 2024-10-01 0001789192 NXTS:FacilityAgreementMember 2024-10-01 2024-10-01 0001789192 srt:MinimumMember 2026-05-27 0001789192 srt:MaximumMember 2026-05-27 0001789192 NXTS:FacilityAgreementMember 2026-05-27 2026-05-27 0001789192 NXTS:FacilityAgreementMember 2026-05-27 0001789192 NXTS:FacilityAgreementMember 2026-01-01 2026-09-30 0001789192 NXTS:FacilityAgreementMember 2026-09-30 0001789192 NXTS:PIPEAgreementAgreementMember 2026-04-08 0001789192 NXTS:AmendedFacilityAgreementMember 2026-04-08 0001789192 2026-10-07 2026-10-07 0001789192 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2026-09-30 0001789192 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2025-12-31 0001789192 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2026-09-30 0001789192 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2025-12-31 0001789192 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2026-09-30 0001789192 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2025-12-31 0001789192 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2026-09-30 0001789192 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2025-12-31 0001789192 us-gaap:MeasurementInputExercisePriceMember us-gaap:WarrantMember 2026-09-30 0001789192 us-gaap:MeasurementInputExercisePriceMember us-gaap:WarrantMember 2025-12-31 0001789192 us-gaap:MeasurementInputSharePriceMember us-gaap:WarrantMember 2026-09-30 0001789192 us-gaap:MeasurementInputSharePriceMember us-gaap:WarrantMember 2025-12-31 0001789192 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001789192 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001789192 us-gaap:PrivatePlacementMember NXTS:SecuritiesPurchaseAgreementMember 2025-01-02 2025-01-02 0001789192 us-gaap:CommonStockMember NXTS:SecuritiesPurchaseAgreementMember 2025-01-02 0001789192 NXTS:SecuritiesPurchaseAgreementMember 2025-01-02 0001789192 2026-04-08 2026-04-08 0001789192 us-gaap:InvestorMember NXTS:PromissoryNoteMember 2025-08-12 0001789192 us-gaap:InvestorMember NXTS:PromissoryNoteMember 2026-01-01 2026-09-30 0001789192 us-gaap:InvestorMember us-gaap:CommonStockMember 2026-01-22 2026-01-22 0001789192 2026-01-22 0001789192 us-gaap:InvestorMember 2026-01-22 2026-01-22 0001789192 NXTS:NewConsultingAgreementMember us-gaap:CommonStockMember 2026-01-08 2026-01-08 0001789192 NXTS:NewConsultingAgreementMember srt:MaximumMember 2026-01-01 2026-09-30 0001789192 NXTS:NewConsultingAgreementMember srt:MinimumMember 2026-07-01 2026-09-30 0001789192 us-gaap:CommonStockMember NXTS:NewConsultingAgreementMember 2026-09-30 0001789192 srt:ExecutiveOfficerMember us-gaap:CommonStockMember 2026-02-09 2026-02-09 0001789192 NXTS:ConsultantsMember us-gaap:CommonStockMember 2026-02-23 2026-02-23 0001789192 NXTS:SecuritiesPurchaseAgreementMember 2026-06-12 0001789192 NXTS:FirstPIPEWarrantsMember 2026-06-12 0001789192 NXTS:FirstPIPEWarrantsMember 2026-06-15 2026-06-15 0001789192 NXTS:FirstPIPEWarrantsMember us-gaap:WarrantMember 2026-06-15 0001789192 NXTS:FirstPIPEWarrantsMember 2026-06-15 0001789192 2026-06-15 0001789192 NXTS:FirstPrivateInvestmentInPublicEquityMember 2026-01-01 2026-09-30 0001789192 NXTS:FirstPrivateInvestmentInPublicEquityMember 2026-07-01 2026-09-30 0001789192 us-gaap:InvestorMember us-gaap:CommonStockMember 2026-06-22 2026-06-22 0001789192 NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-22 0001789192 NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-23 2026-06-23 0001789192 us-gaap:WarrantMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 2026-06-24 0001789192 NXTS:SecondPrivateInvestmentInPublicEquityMember 2026-01-01 2026-09-30 0001789192 NXTS:SecondPrivateInvestmentInPublicEquityMember 2026-07-01 2026-09-30 0001789192 2026-08-31 0001789192 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001789192 NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-01-01 2026-09-30 0001789192 NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-01-01 2026-09-30 0001789192 us-gaap:MeasurementInputPriceVolatilityMember NXTS:FairValueOFWarrantLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputRiskFreeInterestRateMember NXTS:FairValueOFWarrantLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExpectedDividendRateMember NXTS:FairValueOFWarrantLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExpectedTermMember NXTS:FairValueOFWarrantLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExercisePriceMember NXTS:FairValueOFWarrantLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputSharePriceMember NXTS:FairValueOFWarrantLiabilitiesMember 2026-09-30 0001789192 NXTS:FairValueOFWarrantLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputPriceVolatilityMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputPriceVolatilityMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-06-15 0001789192 us-gaap:MeasurementInputRiskFreeInterestRateMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputRiskFreeInterestRateMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-06-15 0001789192 us-gaap:MeasurementInputExpectedDividendRateMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExpectedDividendRateMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-06-15 0001789192 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-06-15 0001789192 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-06-15 0001789192 us-gaap:MeasurementInputExercisePriceMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExercisePriceMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-06-15 0001789192 NXTS:MeasurementInputPotentialAdjustedExercisePriceRangeMember srt:MinimumMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 NXTS:MeasurementInputPotentialAdjustedExercisePriceRangeMember srt:MaximumMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 NXTS:MeasurementInputPotentialAdjustedExercisePriceRangeMember srt:MinimumMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-06-15 0001789192 NXTS:MeasurementInputPotentialAdjustedExercisePriceRangeMember srt:MaximumMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-06-15 0001789192 us-gaap:MeasurementInputSharePriceMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputSharePriceMember NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-06-15 0001789192 NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 NXTS:FairValueOfFirstPIPEWarrantsLiabilitiesMember 2026-06-15 0001789192 us-gaap:MeasurementInputPriceVolatilityMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputPriceVolatilityMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 us-gaap:MeasurementInputRiskFreeInterestRateMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputRiskFreeInterestRateMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 us-gaap:MeasurementInputExpectedDividendRateMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExpectedDividendRateMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 us-gaap:MeasurementInputExercisePriceMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputExercisePriceMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 NXTS:MeasurementInputPotentialAdjustedExercisePriceRangeMember srt:MinimumMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 NXTS:MeasurementInputPotentialAdjustedExercisePriceRangeMember srt:MaximumMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 NXTS:MeasurementInputPotentialAdjustedExercisePriceRangeMember srt:MinimumMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 NXTS:MeasurementInputPotentialAdjustedExercisePriceRangeMember srt:MaximumMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 us-gaap:MeasurementInputSharePriceMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 us-gaap:MeasurementInputSharePriceMember NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-06-24 0001789192 NXTS:FairValueOfSecondPIPEWarrantsLiabilitiesMember 2026-09-30 0001789192 NXTS:TwoThousandTwentyTwoShareIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember NXTS:MrAlonSilbermanMember 2025-10-20 2025-10-20 0001789192 us-gaap:RestrictedStockUnitsRSUMember NXTS:MrAlonSilbermanMember 2026-09-23 2026-09-23 0001789192 NXTS:DirectorsCompensationMember us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001789192 NXTS:DirectorsCompensationMember us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001789192 NXTS:SalariesAndFeesToOfficersMember us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001789192 NXTS:SalariesAndFeesToOfficersMember us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001789192 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001789192 us-gaap:ResearchAndDevelopmentExpense 2026-01-01 2026-09-30 0001789192 us-gaap:ResearchAndDevelopmentExpense 2025-01-01 2025-09-30 0001789192 NXTS:RelatedPartiesAndOfficersMember 2026-09-30 0001789192 NXTS:RelatedPartiesAndOfficersMember 2025-12-31 0001789192 us-gaap:OperatingSegmentsMember NXTS:BiotechnologyActivityMember 2026-01-01 2026-09-30 0001789192 us-gaap:OperatingSegmentsMember NXTS:BiotechnologyActivityMember 2025-01-01 2025-09-30 0001789192 us-gaap:OperatingSegmentsMember NXTS:BiotechnologyActivityMember 2026-07-01 2026-09-30 0001789192 us-gaap:OperatingSegmentsMember NXTS:BiotechnologyActivityMember 2025-07-01 2025-09-30 0001789192 us-gaap:OperatingSegmentsMember NXTS:RenewableEnergyProjectsMember 2026-01-01 2026-09-30 0001789192 us-gaap:OperatingSegmentsMember NXTS:RenewableEnergyProjectsMember 2025-01-01 2025-09-30 0001789192 us-gaap:OperatingSegmentsMember NXTS:RenewableEnergyProjectsMember 2026-07-01 2026-09-30 0001789192 us-gaap:OperatingSegmentsMember NXTS:RenewableEnergyProjectsMember 2025-07-01 2025-09-30 0001789192 us-gaap:OperatingSegmentsMember 2026-01-01 2026-09-30 0001789192 us-gaap:OperatingSegmentsMember 2025-01-01 2025-09-30 0001789192 us-gaap:OperatingSegmentsMember 2026-07-01 2026-09-30 0001789192 us-gaap:OperatingSegmentsMember 2025-07-01 2025-09-30 0001789192 us-gaap:SubsequentEventMember 2026-10-07 2026-10-07 0001789192 us-gaap:SubsequentEventMember 2026-10-07 0001789192 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-10-07 0001789192 us-gaap:SubsequentEventMember 2026-10-15 2026-10-15 0001789192 NXTS:ConsultantsMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001789192 us-gaap:SubsequentEventMember 2026-11-09 2026-11-09 0001789192 us-gaap:SubsequentEventMember NXTS:ThreeConsultantsMember us-gaap:CommonStockMember 2026-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:EUR

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to ____________

 

Commission File No. 001-40403

 

NEXENTIS TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

 

Nevada   26-4684680
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

Pinhas Sapir St. 3, Kiryat HaMada, Ness Ziona, Israel   7403626
(Address of principal executive offices)   (Zip Code)

 

(347) 468-9583

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share   NXTS   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

☐ Large accelerated filer ☐ Accelerated filer
☒ Non-accelerated filer ☒ Smaller reporting company
    ☒ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 16, 2026, the registrant had 666,660 shares of common stock, par value $0.0001 per share, outstanding (as adjusted to give effect to the reverse split of the Company’s common stock at a ratio of 1:7 that became effective on April 8, 2026 and the reverse split of the Company’s common stock at a ratio of 1:5 that became effective on November 9, 2026).

 

 

 

 

 

 

Nexentis Technologies Inc.

 

Quarterly Report on Form 10-Q

 

TABLE OF CONTENTS

 

  Page
Forward-Looking Statements 3
   
PART I - FINANCIAL INFORMATION 4
     
Item 1. Condensed Consolidated Interim Financial Statements (unaudited) 4
     
  Condensed Consolidated Interim Balance Sheets (unaudited) 6
     
  Condensed Consolidated Interim Statements of Comprehensive Loss (unaudited) 7
     
  Condensed Consolidated Interim Statements of Stockholders’ Equity (unaudited) 8
     
  Condensed Consolidated Interim Statements of Cash Flows (unaudited) 10
     
  Notes to Condensed Consolidated Interim Financial Statements 11 - 34
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 35
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 45
     
Item 4. Controls and Procedures 45
     
PART II - OTHER INFORMATION 46
     
Item 1 Legal Proceedings 46
     
Item 1A. Risk Factors 46
     
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 46
     
Item 3 Defaults Upon Senior Securities 46
     
Item 4 Mine Safety Disclosures 46
     
Item 5 Other Information 46
     
Item 6. Exhibits 47
     
SIGNATURES 48

 

2

 

 

FORWARD-LOOKING STATEMENTS

 

Certain information set forth in this Quarterly Report on Form 10-Q (the “Quarterly Report”) including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

 

● Our efforts to complete and integrate current and/or future acquisitions and joint ventures, which could disrupt our current business activities and adversely affect our results of operations or future growth;
   
● Regulatory and compliance changes may adversely impact Solterra’s operations and our joint venture value;
   
● Joint venture and partnership risks may affect Solterra’s projects and our joint venture value;
   
● Our ability to successfully develop and commercialize MitoCareX’s products and obtain required regulatory approvals;
   
● Our ability to continue as a going concern and to obtain the additional capital required to fund our operations and MitoCareX’s development programs;
   
●

Operational and business opportunities available to us following the acquisition of MitoCareX;

 

● Our relationships with third parties, including those that support MitoCareX’s operations;
   
● International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States or Israel;
   
● The evolution of our business strategy may not be successful and we may require additional financing, have increased operational costs or experience other financial harm to our business and financial condition;
   
● The effects of geopolitical events, including instability or the escalation of armed conflicts in the Middle East, including the security situation in Israel;
   
● Our ability to attract and retain sufficient, qualified personnel;
   
● Our ability to obtain or maintain patents or other appropriate protection for the intellectual property;
   
● Our ability to adequately support future growth;
   
● Potential product liability or intellectual property infringement claims;
   
● Portfolio concentration;
   
● Our ability to regain and maintain compliance with the continued listing requirements of the Nasdaq Capital Market;
   
● The market price of our common stock;
   
● International expansion of our business and operations; and
   
● Information with respect to any other plans and strategies for our business.

 

These statements are only predictions and involve known and unknown risks, uncertainties and other factors. Readers are urged to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (the “SEC”). We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.

 

As used in this Quarterly Report and unless otherwise indicated, the terms “Nexentis,” “we,” “us,” “our,” or “our company” refer to Nexentis Technologies Inc., and MitoCareX Bio Ltd., our wholly owned subsidiary (“MitoCareX”) and our wholly owned subsidiary, NITO Renewable Energy, Inc. (“NITO Renewable”), which owns 70% of SB Storage 1 S.R.L.

 

3

 

 

PART I FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

 

NEXENTIS TECHNOLOGIES INC.

 

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

AS OF SEPTEMBER 30, 2026

 

4

 

 

NEXENTIS TECHNOLOGIES INC.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

AS OF SEPTEMBER 30, 2026

USD IN THOUSANDS

 

TABLE OF CONTENTS

 

  Page
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED):  
   
Condensed Consolidated Interim Balance Sheets (unaudited) 6
Condensed Consolidated Interim Statements of Comprehensive Loss (unaudited) 7
Condensed Consolidated Interim Statements of Stockholders’ Equity (unaudited) 8
Condensed Consolidated Interim Statements of Cash Flows (unaudited) 10
Notes to Condensed Consolidated Interim Financial Statements 11 - 34

 

5

 

 

NEXENTIS TECHNOLOGIES INC.

UNAUDITED CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS

(USD in thousands except share and per share data)

 

   September 30,   December 31, 
   2026   2025 
   Unaudited   Audited 
A s s e t s          
Current Assets          
Cash and cash equivalents   2,837    3,832 
Short term bank deposits   3,324    - 
Restricted cash   39    37 
Investment in marketable securities (Notes 5(2), 7)   640    239 
Accounts receivable   -    134 
Short term loan (Note 5(1))   -    396 
Prepaid expenses   454    961 
Other current assets   342    166 
Assets held for sale   -    249 
T o t a l Current assets   7,636    6,014 
           
Long term prepaid expenses   121    161 
Right-of-use asset arising from operating leases   10    16 
Property and equipment, net   82    26 
Investment in Solar Photovoltaic joint venture project (Note 6)   2,513    2,744 
Investment in solar projects under development   1,008    725 
Goodwill (Note 4)   -    6,291 
Intangible asset (Note 3)   4,122    4,428 
T o t a l assets   15,492    20,405 
Liabilities and Shareholders’ Equity          
Current Liabilities          
Short term loan (Note 10 (2))   -    740 
Credit facility (Note 9)   279    - 
Accounts payable   29    6 
Other payable and accrued expenses (Note 3)   1,649    416 
Current warrant liability (Note 9)   -    78 
Liabilities held for sale   -    194 
T o t a l current liabilities   1,957    1,434 
           
Non-current operating lease liabilities   2    8 
Credit facility   -    237 
Stock purchase warrants liabilities (Note 10(1))   10    113 
Contingent consideration (Note 3)   78    2,141 
Deferred taxes liability   671    742 
T o t a l liabilities   2,718    4,675 
Stockholders’ Equity (**)          
Common stock, $ 0.0001 par value (“Common Stock”): 495,000,000 shares authorized as of September 30, 2026 and December 31, 2025; issued and outstanding 297,885 and 79,504 shares as of September 30, 2026 and December 31, 2025, respectively.    -*   -*
Preferred stock, $ 0.0001 par value (“Preferred Stock”): 5,000,000 shares authorized as of September 30, 2026 and December 31, 2025; issued and outstanding 0 shares as of September 30, 2026 and December 31, 2025.    -    - 
Additional paid-in capital    64,187    54,605 
Foreign currency translation adjustments    (29)   (38)
Accumulated deficit    (51,253)   (38,557)
T o t a l Company’s stockholders’ equity    12,905    16,010 
Non-controlling interests    (131)   (280)
T o t a l stockholders’ equity    12,774    15,730 
T o t a l liabilities and stockholders’ equity    15,492    20,405 

 

(*)Less than $1 thousand.
(**)Adjusted to reflect one (1) for seven (7) reverse stock split in April 2026 and one (1) for five (5) reverse stock split in November 2026 (see note 1B).

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

6

 

 

NEXENTIS TECHNOLOGIES INC.

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE GAIN (LOSS)

(USD in thousands except share and per share data)

 

   2026   2025   2026   2025 
   Nine months ended   Three months ended 
   September 30   September 30 
   2026   2025   2026   2025 
                 
Operating expenses:                    
                     
Research and development expenses   (936)   -    (288)   - 
General and administrative expenses, exclusive of depreciation and amortization   (4,141)   (4,201)   (985)   (1,071)
Change in fair value of contingent consideration   349    -    146    - 
Goodwill impairment   (6,291)   -    -    - 
Depreciation and amortization   (316)   -    (107)   - 
Operating loss   (11,335)   (4,201)   (1,234)   (1,071)
Financing income (expense), net   (1,870)   (1,855)   7,067    174 
Other income   386    1,662    -    1,662 
Changes in fair value of investments measured under the fair value option (Notes 5, 6, 7)   (832)   (493)   (855)   (149)
Net gain (loss) before tax   (13,651)   (4,887)   4,978    616 
Income taxes   70    -    24    - 
Net gain (loss) from continuing operation   (13,581)   (4,887)   5,002    616 
Net gain (loss) from discontinued operations (Note 8)   851    (508)   17    (246)

Net gain (loss)

   (12,730)   (5,395)   5,019    370 
Less: Net loss attributable to non-controlling interests   34    122    10    59 
Net gain (loss) attributable to the Company’s stockholders’ equity   (12,696)   (5,273)   5,029    429 
                     
Loss per share from continuing operations (basic) (*)    (69.88)    (232.79)    17.06     24.36 
Gain (loss) per share from discontinued operations (basic) (*)    4.39     (24.84)    0.06     (8.89)
Total gain (loss) per share (basic)    (65.49)    (257.63)    17.12     15.47 
                         
Weighted average number of shares of Common Stock outstanding - basic (*)    193,912     20,463     293,683     27,721 
                         
Gain (loss) per share from continuing operations (diluted) (*)    (74.69)    (476.47)    (0.33)    20.48 
Gain (loss) per share from discontinued operations (diluted) (*)    2.55     (21.29)    0.04     (8.89)
Total Gain (loss) per share (diluted)    (72.14)    (497.76)    (0.29)    11.59 
                         
Weighted average number of shares of Common Stock outstanding – diluted (*)    333,950     23,873     482,401     28,432 
Comprehensive income (loss):                    
Net income (loss)   (12,730)   (5,395)   5,019    370 
Comprehensive income (loss) - Foreign currency translation adjustments   13    (17)   6    (3)
Comprehensive income (loss)   (12,717)   (5,412)   5,025    367 
Other comprehensive income (loss) attributable to non-controlling interests   31    127    2    58 
Comprehensive income (loss) attributable to the Company’s stockholders   (12,686)   (5,285)   5,027    425 

 

(*)Adjusted to reflect one (1) for seven (7) reverse stock split in April 2026 and one (1) for five (5) reverse stock split in November 2026 (see note 1B).

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

7

 

 

NEXENTIS TECHNOLOGIES INC.

 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(USD in thousands, except share and per share data)

 

               Foreign       Total         
   Number       Additional   currency       Company’s   Non-     
   of shares       paid-in   translation   Accumulated   stockholders’   controlling   Total 
   (**)   Amount   capital   adjustments   deficit   equity   interests   equity 
                                 
BALANCE AT DECEMBER 31, 2025   79,504    -*   54,605    (38)   (38,557)   16,010    (280)   15,730 
                                         
Issuance of shares (Note 10(2))   39,636    -*   2,511    -    -    2,511    -    2,511 
Issuance of shares for services   27,184    -*   938    -    -    938    -    938 
Share based compensation   -    -    90    -    -    90    -*   90 
Deconsolidation of Save Foods Ltd   -    -    -    -    -    -    177    177 
Foreign currency translation adjustments   -    -    -    3    -    3    1    4 
Net loss for the period   -    -    -    -    (6,580)   (6,580)   (9)   (6,589)
BALANCE AT MARCH 31, 2026   146,324    -*   58,144    (35)   (45,137)   12,972    (111)   12,861 
                                         
Issuance of shares (Note 10(6))   62,379    -*   -    -    -    -*   -    -*
Issuance of shares (Note 10(7))   82,204    -*   -    -    -    -*   -    -*
Share based compensation   -    -    70    -    -    70    -    70 
Capital contribution from non-controlling interests   -    -    6    -    -    6    2    8 
Foreign currency translation adjustments   -    -    -    2    -    2    1    3 
Net loss for the period   -    -    -    -    (11,145)   (11,145)   (15)   (11,160)
BALANCE AT JUNE 30, 2026   290,907    -*   58,220    (33)   (56,282)   1,905    (123)   1,782 
                                         
Issuance of shares upon achievement of contingent consideration milestone (Note 3)   6,978    -*   161    -    -    161    -    161 
Share based compensation   -    -    217    -    -    217    -    217 
Reclassification of warrants liabilities into equity (Notes 9, 10(6) and 10(7))   -    -    5,589    -    -    5,589    -    5,589 
Foreign currency translation adjustments   -    -    -    4    -    4    2    6 
net gain for the period   -    -    -    -    5,029    5,029    (10)   5,019 
BALANCE AT SEPTEMBER 30, 2026   297,885    -*   64,187    (29)   (51,253)   12,905    (131)   12,774 

 

8

 

 

NEXENTIS TECHNOLOGIES INC.

 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(USD in thousands, except share and per share data)

 

               Foreign       Total         
   Number       Additional   currency       Company’s   Non-      
   of shares       paid-in   translation   Accumulated   stockholders’   controlling   Total 
   (**)   Amount   capital   adjustments   deficit   equity   interests   equity 
                               
BALANCE AT DECEMBER 31, 2024   10,096    -*   39,328    (26)   (34,553)   4,749    (176)   4,573 
                                         
Issuance of shares for private investment in public equity (PIPE) agreement   4,106    -*   1    -    -    1    -    1 
Warrant exercises   598    -*   387    -    -    387    -    387 
Share based compensation   -    -    -*    -    -    -*    -*    -* 
Foreign currency translation adjustments   -    -    -    (4)   -    (4)   (2)   (6)
Net loss for the period   -    -    -    -    (1,193)   (1,193)   (64)   (1,257)
BALANCE AT MARCH 31, 2025   14,800    -*   39,716    (30)   (35,746)   3,940    (242)   3,698 
                                         
Issuance of shares for services   3,598    -*   1,955    -    -    1,955    -    1,955 
Issuance of shares for purchase agreement   552    -*   300    -    -    300    -    300 
Warrant exercises   5,893    -*   4,085    -    -    4,085    -    4,085 
Share based compensation   -    -    -*   -    -    -*   -*   -*
Foreign currency translation adjustments   -    -    -    (6)   -    (6)   (2)   (8)
Deconsolidation of NTWO OFF Ltd   -    -    -    -    -    -    29    29 
Net loss for the period   -    -    -    -    (4,509)   (4,509)   1    (4,508)
BALANCE AT JUNE 30, 2025   24,843    -*   46,056    (36)   (40,255)   5,765    (214)   5,551 
                                         
Issuance of shares for services   2,451    -*   714    -    -    714    -    714 
Issuance of shares for purchase agreement   11,954    -*   1,672    -    -    1,672    -    1,672 
Warrant exercises   213    -*   127    -    -    127    -    127 
Capital contribution from non-controlling interests   -    -    48    -    -    48    20    68 
Commitment to issue shares   -    -    177    -    -    177    -    177 
Share based compensation   -    -    -*   -    -    -*   -*   -*
Foreign currency translation adjustments   -    -    -    (2)   -    (2)   (1)   (3)
Net gain for the period   -    -    -    -    429    429    (59)   370 
BALANCE AT SEPTEMBER 30, 2025   39,461    -*   48,794    (38)   (39,826)   8,930    (254)   8,676 

 

(*)Less than $1 thousand.
(**)Adjusted to reflect one (1) for seven (7) reverse stock split in April 2026 and one (1) for five (5) reverse stock split in November 2026 (see note 1B).

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

9

 

 

NEXENTIS TECHNOLOGIES INC.

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(USD in thousands except share and per share data)

 

   2026   2025 
   Nine months ended 
   September 30 
   2026   2025 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss   (12,730)   (5,395)
Adjustments to reconcile net loss to net cash used in operating:          
Depreciation and amortization   322    8 
Deferred income taxes   (71)   - 
Issuance of shares to employees and service providers   923    2,035 
Share-based compensation to employees and directors   377    1 
Gain from sales of property and equipment   -    (3)
Expenses funded by non-controlling interests   8    68 
Gain from standby equity purchase agreement II   (386)   (1,662)
Expenses from standby equity purchase agreement II   -    182 
Interest in respect of loans   460    106 
Gain from deconsolidation of subsidiary   (898)   (44)
Goodwill impairment   6,291    - 
Accrued interest income on short-term bank deposits   (24)   - 
Change in fair value of non-current warrant liability   2,336    (130)
Change in fair value of credit facility   42    63 
Change in fair value of stock purchase warrant liabilities   (1,078)   1,540 
Change in fair value of investment in nonconsolidated affiliate   -    603 
Change in fair value of short-term loan   (121)   20 
Change in fair value of long-term loan   -    (47)
Change in fair value of Solar Photovoltaic joint venture project   149   (143)
Change in fair value of investment in marketable securities   792    67 
Change in fair value of contingent consideration   (349)   - 
Decrease (increase) in accounts receivable   130    141 
Decrease (increase) in inventory   (3)   5 
Decrease (increase) in prepaid expenses and other current assets   647    (29)
Increase (decrease) in accounts payable   (22)   10 
Increase in other payables and accrued expenses   19    291 
Decrease in operating lease expense   8    13 
Change in operating lease liabilities   (8)   (11)
Net cash used in operating activities   (3,186)   (2,311)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Investment in short-term bank deposits   (3,300)   - 
Investment in solar projects under development   (269)   (482)
Purchase of property   (72)   - 
Proceeds from sales of property and equipment   -    3 
Cash and cash equivalents deconsolidated upon loss of control (Note 8)   (210)   (25)
Short term loan granted   -    (786)
Proceeds from repayments of loans related to Solar Photovoltaic projects   604    - 
Loan to Solar Photovoltaic joint venture project   (104)   (608)
Net cash used in investing activities   (3,351)   (1,898)
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from credit facility   -    1,105 
Repayment of credit facility   -    (1,158)
Proceeds from issuance of shares and warrants   4,150    1,500 
Proceeds from exercise of warrants   -    1,830 
Proceeds from promissory note   -    1,485 
Payment of contingent consideration   

(470

)   

-

 
Repayments of short-term loan   (1,200)   - 
Net proceeds from issuance of shares pursuant to Purchase Agreement   2,896    3,335 
Net cash provided by financing activities   5,376    8,097 
           
Effect of exchange rate changes on cash and cash equivalents   24    (27)
           
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH   (1,137)   3,861 
           
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD   4,013    2,209 
           
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD   2,876    6,070 
Cash paid during the period for:        
Interest   26    77 
Non cash transactions:          
Initial recognition of operating lease liability and a corresponding right-of- use asset   -    24 
Reclassification of warrant liabilities to equity upon exercise of warrants   -    2,769 
Issuance of shares for future credit line   -    300 
Non-cash financing costs related to issuance of promissory note   -    477 
Reclassification of contingent cash consideration to accrued expenses   

1,553

    

-

 
Reclassification of warrant liabilities into equity   5,589    - 
Issuance of shares upon achievement of contingent consideration milestone   161    - 
Issuance of shares for future services   15    - 
Investment in marketable securities in exchange for shares of a subsidiary   1,192    - 

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements

 

10

 

 

NEXENTIS TECHNOLOGIES INC.

 NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 1 – GENERAL

 

A.Operations

 

Nexentis Technologies Inc. (formerly N2OFF, Inc.) (the “Company”) was incorporated on April 1, 2009, under the laws of the State of Delaware. On November 6, 2023, the Company was reincorporated into the State of Nevada. The Company’s Common Stock is listed on the Nasdaq Capital Market under the symbol “NXTS”.

 

The Company is engaged in renewable energy projects through its wholly owned subsidiary NITO Renewable Energy Inc., which was incorporated in the State of Nevada on February 10, 2025. The Company is also engaged in pharmaceuticals operations for the development of targeted cancer therapeutics for Non-Small Cell Lung Cancer, through its wholly-owned subsidiary MitoCareX Bio Ltd. (“MitoCareX”), a private entity incorporated in the State of Israel acquired by the Company on October 20, 2025.

 

Under its renewable energy operations, on February 24, 2025, the Company entered into a shareholders agreement with Solterra Brand Services Italy SRL (“SB”) and SB Impact 4 LTD (which on April 14, 2025 changed its name to SB Storage 1 S.R.L), a wholly owned subsidiary of SB (“SBI4”) pursuant to which the Company purchased, through its subsidiary NITO Renewable Energy Inc., 70% of SBI4 shares (on a fully diluted basis) from SB.

 

Additionally, through its 98.48% owned subsidiary, Save Foods Ltd., the Company was previously engaged, from April 2009 through March 2026, in the development of solutions for the food industry aimed at improving food safety and shelf life of fresh produce. On March 15, 2026, the Company closed a transaction with Voice Assist, Inc., a public company incorporated under the laws of the State of Nevada (“Voice Assist”) for the sale of 100% of the Company’s equity interests in Save Foods Ltd. See Note 7 below.

 

B.Reverse stock split

 

On April 8, 2026, the Company effected a 1-for-7 reverse stock split of the Company’s outstanding Common Stock (the “April Reverse Stock Split”).

 

As a result of the April Reverse Stock Split, every seven shares of the Company’s outstanding Common Stock prior to the effect of that amendment were combined and reclassified into one share of the Company’s Common Stock. No fractional shares were issued in connection with or following the reverse split and the shares were rounded to the nearest whole number. The authorized capital and par value of the Common Stock remained unchanged.

 

On November 9, 2026, subsequent to the balance sheet date and prior to the issuance of these condensed consolidated financial statements, the Company effected an additional 1-for-5 reverse stock split of its outstanding Common Stock (the “November Reverse Stock Split”). As a result, every five shares of the Company’s outstanding Common Stock were combined and reclassified into one share of Common Stock.

 

All shares, stock options, warrants and per share information in these condensed consolidated financial statements have been retrospectively adjusted to reflect the effects of both reverse stock splits on a retroactive basis.

 

11

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 1 – GENERAL (continued)

 

C.Going concern uncertainty

 

Since inception, the Company has incurred significant losses and negative cash flows from operations and has an accumulated deficit of $51 million. The Company has financed its operations mainly through financing by the issuance of the Company’s equity from various investors.

 

The Company’s management expects that the Company will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected cash flows and cash balances as of September 30, 2026, management currently is of the opinion that its existing cash will not be sufficient to fund its operations during the twelve months following the date of issuance of these financial statements. As a result, there is substantial doubt regarding the Company’s ability to continue as a going concern.

 

Management plans to continue securing sufficient financing through the sale of additional equity securities or capital inflows from strategic partnerships. However, additional funds may not be available when the Company needs them, on favorable terms, or at all. If the Company is unsuccessful in securing sufficient financing, it may need to cease operations.

 

The financial statements do not include adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern.

 

D.Israel –war

 

On February 28, 2026, the United States and Israel preemptively attacked Iran to eliminate its nuclear and ballistic missile capabilities. As part of this conflict, Iran launched missile and drone attacks toward population centers and military installations in Israel, Europe and neighboring countries in the Gulf region, and also launched counter strikes against U.S. forces and allied bases throughout the Gulf region. These events have resulted in civilian casualties and property damage in Israel. In early March 2026, Hezbollah joined the conflict and carried out missile attacks against Israel, leading to Israeli retaliatory strikes and an extended ground incursion, with Israeli forces occupying a zone approximately 10 kilometers deep in southern Lebanon. While temporary ceasefires between the United States, Israel, and Iran, and between Israel and Lebanon, were reached in April 2026, hostilities between Israel and Hezbollah remain ongoing with occasional flare ups between the United States and Iran, there can be no assurance that the temporary ceasefires will be upheld or that a permanent ceasefire will be reached, and the situation remains volatile and highly unstable.

 

As a significant portion of the Company’s activities, including research and development activities conducted through MitoCareX, are located in Israel, and members of the Company’s management and certain employees and consultants are located in Israel, the Company’s operations may be affected by economic, political, geopolitical and military conditions affecting Israel. Any escalation or expansion of the war could have a negative impact on both global and regional conditions and may adversely affect the Company’s business, financial condition, and results of operations.

 

The Company is unable to predict the duration or severity of the current conflict or any potential escalation. To date, the conflict has resulted primarily in certain delays in the Company’s research and development activities, including activities conducted by MitoCareX. The Company is continuing to regularly follow developments on the matter and is examining the effects on its operations and the value of its assets.

 

12

 

 

NEXENTIS TECHNOLOGIES INC.

 NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

 

Basis of presentation

 

The condensed interim consolidated financial statements included in this Quarterly Report are unaudited. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company’s financial position as of September 30, 2026, and its results of operations, changes in stockholders’ equity, and cash flows for the nine and three months ended September 30, 2026 and 2025. The results of operations for the nine and three months ended September 30, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any other future annual or interim period. These financial statements should be read in conjunction with the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 31, 2026. The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2025 included in such Form 10-K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies.

 

Use of Estimates

 

The preparation of unaudited condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to impairment assessment of intangible assets and goodwill and calculation of fair value of the financial instruments. A change in estimates, including a change in the overall market value of the Company, could require reassessments of the items noted above.

 

Principles of consolidation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. During the nine months ended September 30, 2026, the Company deconsolidated Save Foods Ltd. as of the date control was lost.

 

Short term bank deposits

 

Short term bank deposits consist of deposits held with financial institutions with original maturities of more than three months but not exceeding one year. These deposits are recorded at amortized cost, including accrued interest, which approximates their fair value due to their short-term maturities. Interest income is recognized as earned and included in financing expenses, net, in the consolidated interim statements of comprehensive gain (loss).

 

Discontinued operations

 

A component of an entity is identified as operations and cash flows that can be clearly distinguished, operationally and financially, from the rest of the entity. Under ASC 205-20, “Presentation of Financial Statements - Discontinued Operations” (“ASC 205-20”), a discontinued operation is a component of an entity that either has been disposed of, or is classified as held for sale and represents a strategic shift that has or will have a major effect on the entity’s operations and financial results, or a newly acquired business or nonprofit activity that upon acquisition is classified as held for sale. Discontinued operations are presented separately from continuing operations in the consolidated statements of Operations.

 

13

 

 

NEXENTIS TECHNOLOGIES INC.

 NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continued)

 

Investment in equity securities

 

Investments in equity securities with readily determinable fair values, for which the Company does not have the ability to exercise significant influence over the investee, are accounted for in accordance with ASC 321, Investments—Equity Securities and are measured at fair value. Changes in fair value are recognized in the unaudited condensed consolidated statements of operations. Fair value is generally determined based on quoted market prices when available.

 

Goodwill and intangible asset

 

Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets acquired in business combinations accounted for in accordance with the “purchase method” and is allocated to reporting units at acquisition. Goodwill is not amortized but rather tested for impairment at least annually in accordance with the provisions of ASC Topic 350, “Intangibles - Goodwill and Other”. The Company performs its goodwill annual impairment test for the reporting units at December 31 of each year, or more often if indicators of impairment are present.

 

Intangible assets with finite lives are amortized using the straight-line basis over their useful lives, to reflect the pattern in which the economic benefits of the intangible assets are consumed or otherwise used up.

 

The evaluation of goodwill impairment and the determination of useful lives and amortization of intangible assets involves significant judgments and estimates, including assumptions related to future cash flows, discount rates and market conditions. The determination of the fair value of reporting units is inherently subjective, as it requires the use of valuation models and unobservable inputs. Accordingly, this assessment is considered a critical accounting estimate, and actual results may differ materially from those estimates.

 

As of September 30, 2026, a non-cash goodwill impairment loss of $6.3 million, was recognized for the MitoCareX reporting unit. For further details, see Note 4.

 

Impairment of long-lived assets

 

Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Assets are categorized and evaluated for impairment at the lowest level of identifiable cash flows. In the event that the sum of the expected future undiscounted cash flows expected to be generated by the long-lived assets is less than the carrying amount of such assets, an impairment charge would be recognized and the assets would be written down to their estimated fair values. The Company did not record any impairment of long-lived assets for any of the periods presented.

 

Fair value

 

Fair value of certain of the Company’s financial instruments including cash, accounts payable, accrued expenses, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements” which defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements.

 

14

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continued)

 

Fair value (continued)

 

Fair value, as defined by ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise.

 

Valuation techniques are generally classified into three categories: (i) the market approach; (ii) the income approach; and (iii) the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs.

 

Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows:

 

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.

 

Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and

 

Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values.

 

Fair value measurements are required to be disclosed by the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), (ii) segregating those gains or losses included in earnings, and (iii) a description of where those gains or losses included in earning are reported in the statement of operations.

 

The Company’s financial assets that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows:

 

   Level 1   Level 2   Level 3   Total 
   As of September 30, 2026 
   Level 1   Level 2   Level 3   Total 
   US$ 
                 
Assets:                    
Investment in Solterra’s shares   243    -    -    243 
Investment in Voice Assist’s shares   397    -    -    397 
Loan to Solar Photovoltaic joint venture project   -    -    2,513    2,513 
Total assets   640    -    2,513    3,153 

 

15

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continued)

 

Fair value (continued)

 

   Level 1   Level 2   Level 3   Total 
   As of December 31, 2025 
   Level 1   Level 2   Level 3   Total 
   US$ 
                 
Assets:                    
Investment in Solterra’s shares   239    -    -    239 
Loan to Solar Photovoltaic joint venture project   -    -    2,744    2,744 
Convertible loan to Solterra   -    -    396    396 
Total assets   239    -    3,140    3,379 

 

The following table presents the changes in fair value of the level 3 assets for the period from December 31, 2025 through September 30, 2026:

 

  

Loan to Solar

photovoltaic

joint venture

project

  

Convertible

loan to

Solterra

   Total 
Assets:               
Outstanding at December 31, 2025   2,744    396    3,140 
Additions during the period   104    -    104 
Repayments during the period   (172)   (432)   (604)
Reclassification to other receivables upon settlement of loans   (14)   (85)   (99)
Changes in fair value   (149)   121    (28)
Outstanding at September 30, 2026   2,513    -    2,513 

 

The Company’s financial liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows:

 

   Level 1   Level 2   Level 3   Total 
   As of September 30, 2026 
   Level 1   Level 2   Level 3   Total 
   US$ 
                 
Liabilities:                    
Contingent consideration   -    -    78    78 
Stock purchase warrants liability   -    -    10    10 
Credit facility   -    -    279    279 
Total liabilities   -    -    367    367 

 

16

 

 

NEXENTIS TECHNOLOGIES INC.

 NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continued)

 

Fair value (continued)

 

   Level 1   Level 2   Level 3   Total 
   As of December 31, 2025 
   Level 1   Level 2   Level 3   Total 
   US$ 
                 
Liabilities:                    
Contingent consideration   -    -    2,141    2,141 
Stock purchase warrants liability   -    -    113    113 
Warrant liabilities to Pure Capital   -    -    78    78 
Credit facility   -    -    237    237 
Total liabilities   -    -    2,569    2,569 

 

The following table presents the changes in fair value of the level 3 liabilities for the period from December 31, 2025 through September 30, 2026:

 

  

Stock

purchase

warrants

liability

  

Warrant

liabilities to

Pure Capital

  

Credit

facility

  

Contingent

consideration

   Total 
   US$ 
Liabilities:                    
Outstanding at December 31, 2025   113    78    237    2,141    2,569 
Reclassification of contingent consideration liabilities to other payables and accrued expenses   -    -    -    (1,553)   (1,553)
Issuance of warrant liabilities   4,150    -    -    -    4,150 
Day-one loss on issuance of warrant liabilities   2,065   -    -    -    2,065
Changes in fair value, including effect of warrant modification   -    7,507    -    -    7,507 
Reclassification of warrant liabilities to equity   (3,175)   (2,414)   -    -    (5,589)
Issuance of shares upon achievement of contingent consideration milestone   -    -    -    (161)   (161)
Changes in fair value   (3,143)   (5,171)   42    (349)   (8,621)
Outstanding at September 30, 2026   10    -    279    78    367 

  

17

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 3 – CONTINGENT CONSIDERATION AND INTANGIBLE ASSET

 

On October 20, 2025, the Company completed the acquisition of MitoCareX from SciSparc Ltd., Dr. Alon Silberman and Prof. Ciro Leonardo Pierri (collectively, the “Sellers”), which became a wholly-owned subsidiary of the Company. For additional information regarding the acquisition and the purchase price allocation, see Note 4 to the Company’s annual consolidated financial statements for the year ended December 31, 2025.

 

As part of the consideration for the acquisition, the Sellers are entitled to receive additional shares of the Company’s Common Stock, for no additional consideration, in an aggregate amount of up to 25% of the issued and outstanding capital stock of the Company on a fully-diluted basis calculated immediately following the closing date, which was determined to be 27,905 shares of Common Stock subject to MitoCareX meeting certain milestones (the “Contingent share consideration”).

 

During the nine months ended September 30, 2026, the first milestone was achieved, resulting in the Sellers becoming entitled to receive 6,978 shares of the Company’s Common Stock.

 

The Company concluded that the Contingent share consideration failed the indexation guidance of ASC 815-40 and accordingly this contingent commitment to issue shares was classified as a liability. The liability is remeasured to fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations. The Contingent share consideration was calculated as of September 30, 2026, at approximately $78.

 

Furthermore, as additional consideration for the acquisition, the Sellers are entitled to receive, collectively, 30% of the gross proceeds of each financing transaction closed by the Company within five years from the closing date, up to a maximum aggregate amount of $1,600 (the “Contingent cash consideration”). The Contingent cash consideration is remeasured to fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations.

 

During the nine months ended September 30, 2026, financing transactions completed by the Company caused the maximum aggregate Contingent Cash Consideration of $1,600 to become fixed and no longer subject to fair value remeasurement. The Company paid $470 during the period, and the remaining unpaid amount of $1,130 was included in accrued expenses and other payables as of September 30, 2026. Accordingly, no Contingent Cash Consideration remained subject to fair value remeasurement as of September 30, 2026.

 

18

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 4 – GOODWILL IMPAIRMENT ASSESSMENT

 

As of March 31, 2026, the Company performed an interim quantitative goodwill impairment analysis for the “MitoCareX” reporting unit, to which the Company’s goodwill is allocated, due to indicators identified during the period, including, among other things, a significant decline in the price of the Company’s Common Stock and corresponding market capitalization since the Company’s most recent goodwill impairment assessment, the Company’s market capitalization being below its stockholders’ equity, as well as increased uncertainty in the macroeconomic and geopolitical environment. Due to these indicators, the Company engaged a third-party valuation specialist to assist management in performing the quantitative goodwill impairment assessment as of March 31, 2026.

 

The quantitative assessment was performed by measuring the reporting unit’s fair value using the income approach, based on the expected present value of estimated future cash flows. The fair value measurement is categorized as Level 3 within the fair value hierarchy due to the use of unobservable inputs, such as financial projections, terminal growth rate, and discount rate. In applying the income approach, the Company evaluated the reasonableness of the inputs and outcomes of its discounted cash flow analysis against available market data. As part of this analysis, the Company concluded that the discount rate used in the current impairment analysis reflects higher market-based and MitoCareX-specific risk premiums, which are associated with changes in global macroeconomic conditions in 2026, including heightened geopolitical risks related to operations in the Middle East, particularly the conflict between Israel and Iran.

 

The results of the impairment analysis indicated that the carrying value of the MitoCareX reporting unit was in excess of its fair value. Therefore, the Company recorded during the nine months ended September 30, 2026 a non-cash impairment loss of $6.3 million under “goodwill impairment” in the Condensed Consolidated Statements of Operations.

 

NOTE 5 – INVESTMENT AND LOAN TO SOLTERRA

 

1.On June 30, 2024, the Company entered into a 24-month Loan Agreement with Solterra Renewable Energy Ltd. (“Solterra”) and other lenders, under which the Company committed €375 thousands (approximately $406) out of a total €500 thousands principal amount. The loan bears annual interest of 7%, payable beginning June 30, 2025. Solterra shall have the option to convert the loan into shares of Solterra Energy Ltd. (“SE”), at the lowest price per share under which SE raises capital during the period from the Loan Agreement date through conversion. If the loan is not converted or repaid in full within nine months from the closing date of the merger involving SE, the interest rate increases to 12% per annum. On October 28, 2025, the Company entered into an amendment to the Loan Agreement, pursuant to which the accrued interest through June 30, 2025, was added to the loan principal and bears interest from that date.

 

On June 30, 2026, the Company entered into an assignment agreement with Solterra and SE, pursuant to which, subject to the completion of the transaction contemplated by the agreement with Sunflower Sustainable Investments Ltd. (“Sunflower”), the Company agreed to assign to SE all of its rights under the Loan Agreement in consideration for an amount equal to the outstanding loan balance, including accrued interest and linkage differences.

 

19

 

 

NEXENTIS TECHNOLOGIES INC.

 NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 5 – INVESTMENT AND LOAN TO SOLTERRA (continued)

 

Following the completion of the transaction with Sunflower, the assignment of the Company’s rights under the Loan Agreement became effective. Accordingly, the Company derecognized the original loan receivable and recognized a receivable from SE for the consideration due under the assignment agreement.

 

On July 31, 2026, the Company received €375 thousand (approximately $432) as partial settlement of the assignment consideration in an amount equal to the original loan principal. As of September 30, 2026, the remaining unpaid consideration amounted to €75 thousands (approximately $85) and was included in other current assets.

 

The Company’s chairman of the board of directors also serves as a director of SE.

 

2.During 2024, the Company acquired 267,000 shares of SE.

 

The investment is measured at fair value in accordance with ASC 321. The fair value of the investment as of September 30, 2026, was $243, based on quoted prices in active markets.

 

NOTE 6 – SOLAR PHOTOVOLTAIC JOINT VENTURE PROJECT

 

1.On July 31, 2024, the Company entered into a Loan and Partnership Agreement with Horizons RES PE1 UG (haftungsbeschränkt) & Co. KG a German partnership (the “Partnership”), Solterra, and other lenders, under which the Company committed €1,560 thousands (approximately $1,716) loan for solar energy projects. The loan bears interest of 7% annually and matures upon the earlier of the sale of the Partnership or five years from the agreement date. The Company’s loan is secured by a lien on Solterra’s interests in the Partnership, and all loans from Solterra are subordinated. The lenders are entitled to 50% of the Partnership’s profits, with the Company entitled to 25% through one of several profit rights alternatives.

 

During 2025, the Company and the other lenders entered into several amendments and additional loan agreements in connection with the Germany project, pursuant to which the Company committed to provide additional funding, including €19 thousand under a bridge loan, €450 thousand under Addendum No. 2, and €210 thousand under an additional loan agreement dated December 24, 2025. Such additional amounts generally bear interest at 7% annually and are intended to support the development of the battery energy storage system and photovoltaic facility, including activities aimed at achieving Ready-to-Build status.

 

On June 4, 2026, the parties entered into Addendum No. 3 to the Loan and Partnership Agreement. Subject to the closing of the contemplated transaction involving Sunflower., the Addendum provides, among other things, for the repayment of 10% of the outstanding loan and accrued interest, a corresponding 10% reduction in the remaining funding commitment, a reduction in the lenders’ aggregate profit rights from 50% to 45%, and an option to purchase and redeem the lenders’ remaining profit rights. The related closing occurred in July 2026, during the three months ended September 30, 2026.

 

As of September 30, 2026, the Company has funded €1,545 thousands (approximately $1,750).

 

The Company’s interest in the Partnership was evaluated under ASC 810-10, and the Company determined that the Partnership is not subject to consolidation by the Company. Accordingly, the Partnership is not consolidated in the Company’s consolidated financial statements.

 

20

 

 

NEXENTIS TECHNOLOGIES INC. 

 NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 6 – SOLAR PHOTOVOLTAIC JOINT VENTURE PROJECT (continued)

 

The Company elected to account for the Loan and Partnership Agreement under the fair value option in accordance with ASC 825. The Company estimated the fair value of the Loan and Partnership Agreement using a third-party appraiser and various assumptions such as, probability of completion of the project based on key milestones, scenarios for the expected project’s cash realization value (including expected power of the project, selling price per megawatt, and loan repayment dates). The projected net cash flows were discounted using an interest rate appropriate for similar projects. The result was adjusted to the probability for the completion of the project as of the valuation date.

 

The interest rate was determined at 8.97% as of September 30, 2026. The Company calculated the Loan Agreement and the fair value of the Company’s interest in the Partnership and Loan amounted to €2,218 thousands (approximately $2,513) as of September 30, 2026.

 

2.On May 6, 2025, the Company, together with other investors, entered into a loan agreement with Soltra Renewable Energies Ltd. (the “Borrower”), an Israeli traded company, to finance the development of a battery storage project in Poland known as the “Pikozow Project.” Under the agreement, the Company extended a loan in the principal amount of €150 thousand (approximately $177).

 

In the event the project is sold to a third party not related to the Borrower during a 30 months term, the Company will be entitled to repayment of the principal plus a pro-rata share (15%) of 50% of the net profit from the sale, as defined in the agreement.

 

If the project is not sold by the end of the term of the loan, the loan will bear annual interest of 7%, and the total amount due (principal and interest) will be repaid at maturity. The agreement does not provide for early repayment.

 

The Company assessed its involvement in the Pikozow Project in accordance with ASC 810-10, Variable Interest Entities (VIE), and concluded that the Borrower does not meet the definition of a VIE. Accordingly, no consolidation is required.

 

On June 4, 2026, the Company assigned its rights under the loan agreement to Solterra, as part of the transaction described above. Upon effectiveness of the assignment, the Company’s rights to participate in future profits from the project were terminated, and the loan receivable was derecognized.

 

The Company received €150 thousand (approximately $173), representing partial settlement of the assignment consideration corresponding to the outstanding loan principal. As of September 30, 2026, the remaining unpaid consideration, attributable to accrued interest, amounted to approximately €12 thousand (approximately $14) and was included in other current assets.

 

21

 

 

NEXENTIS TECHNOLOGIES INC.

 NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 7 – SHARE EXCHANGE TRANSACTION AND INVESTMENT IN VOICE ASSIST, INC.

 

On January 13, 2026, the Company entered into a Securities Exchange Agreement with Voice Assist, Inc. (“Voice Assist”), pursuant to which the Company agreed to transfer to Voice Assist approximately 98% of the issued and outstanding share capital of Save Foods Ltd., subject to customary closing conditions.

 

In addition, the Company entered into a Services Agreement with Voice Assist pursuant to which the Company will provide advisory and related services. The consideration under the Services Agreement includes deferred cash payments contingent upon future financing transactions of Voice Assist, royalty-based consideration from future projects, and contingent proceeds related to certain claims, as defined in the agreement. The Services Agreement does not have a specified termination date. The Company expects its continuing involvement under the Services Agreement to continue for as long as the advisory and related services are required by Voice Assist and the related contingent consideration arrangements remain in effect; however, the Company cannot reasonably estimate the exact period during which such involvement will continue.

 

On March 15, 2026, the Company closed the transaction for the sale of its equity interests in Save Foods Ltd., in which the Company previously held approximately 98% of its share capital. As a result of the closing and the terms of the agreement, the Company lost control of Save Foods Ltd. and deconsolidated Save Foods Ltd. as of March 15, 2026.

 

The consideration received by the Company consisted of 60,198,540 shares of Voice Assist common stock, representing 19.99% of Voice Assist on a fully diluted basis as of immediately following the closing, however, as a result of Voice Assist’s capital structure, including outstanding preferred shares that carry voting rights greater than those of the common stock, the Company’s voting interest in Voice Assist is lower than its percentage ownership on a fully diluted basis. The fair value of the Voice Assist shares received was approximately $1,192, based on the quoted market price of Voice Assist’s common stock on the closing date.

 

The Company evaluated whether it has the ability to exercise significant influence over Voice Assist in accordance with ASC 323. Based on the Company’s ownership percentage and other relevant facts and circumstances, including the absence of board representation, participation in policy-making processes, or other rights to participate in operating or financial decisions of Voice Assist, the Company concluded that it does not have significant influence over Voice Assist.

 

Accordingly, the investment in Voice Assist is accounted for as an equity security in accordance with ASC 321 and is measured at fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations.

 

As of September 30, 2026, the fair value of the Company’s investment in Voice Assist was approximately $397, based on the quoted market price of Voice Assist’s common stock as of that date. During the nine and three months ended September 30, 2026, the Company recognized losses of approximately $795 and $596, respectively, resulting from changes in the fair value of the investment.

 

22

 

 

NEXENTIS TECHNOLOGIES INC.

 NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 8 – DISCONTINUED OPERATIONS

 

Disposal of Save Foods Ltd.

 

During 2025, the Company committed to a plan to sell Save Foods Ltd. (the Company’s pathogen prevention and shelf-life extension segment) and determined that the disposal represented a strategic shift that had a major effect on the Company’s operations and financial results. Accordingly, the operations of Save Foods Ltd. were classified as discontinued operations in accordance with

 

ASC 205-20.

 

On March 15, 2026, the Company closed the transaction for the sale of its equity interests in Save Foods Ltd., in which the Company previously held approximately 98% of its share capital. Following the closing, the Company lost control of Save Foods Ltd. and deconsolidated Save Foods Ltd. as of March 15, 2026, see also Note 7.

 

As of September 30, 2026, following the closing of the transaction, the assets and liabilities of Save Foods Ltd. were no longer included in the Company’s consolidated balance sheet.

 

During the nine months ended September 30, 2026, the Company recognized a gain from deconsolidation of Save Foods Ltd. of approximately $898, which is included in net gain from discontinued operations.

 

Results of operations of Save Foods Ltd. included in discontinued operations were as follows:

 

  

   2026   2025   2026   2025 
   Nine months ended   Three months ended 
   September 30   September 30 
   2026   2025   2026   2025 
                 
Revenues from sales of products   60    68    -    2 
Cost of sales   (2)   (19)   -    (2)
Gross profit   58    49    -    - 
                     
Research and development expenses   -    (81)   -    (52)
Selling and marketing expenses   (28)   (130)   -    (34)
General and administrative expenses   (74)   (416)   -    (169)
Operating income (loss)   (44)   (578)   -    (255)
Finance income (expenses), net   (3)   22    -    9 
Other income   -    3    -    - 
Gain (loss) before gain from deconsolidation   (47)   (553)   -    (246)
Gain from deconsolidation of subsidiary   898    -    17    - 
Net gain (loss) from discontinued operations   851    (553)   17    (246)
Less: net loss from discontinued operations attributable to non-controlling interests   1    8    -    4 
Net income (loss) from discontinued operations attributable to the Company   852    (545)   17    (242)

 

23

 

 

NEXENTIS TECHNOLOGIES INC.

 NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 8 –DISCONTINUED OPERATIONS (continued)

 

Cash flows from discontinued operations for the nine months ended September 30, 2026 and 2025:

 

   2026   2025 
   Nine months ended 
   September 30 
   2026   2025 
           
Net cash used in operating activities   (27)   (493)
           
Net cash used in investing activities   -    3 

 

Supplemental disclosure of Deconsolidation of Save Foods Ltd. as of March 15, 2026:

 

   USD in thousands 
A. Net assets deconsolidated     
Total assets deconsolidated   488 
Total liabilities deconsolidated   (371)
Net assets deconsolidated   117 
      
B. Reconciliation of gain on deconsolidation     
Noncash consideration — Voice Assist shares   1,192 
Net assets deconsolidated   (117)
Non-controlling interest deficit derecognized   (177)
Gain from deconsolidation of subsidiary   898 
      
C. Net cash flows from deconsolidation     
Cash consideration received   - 
Cash and cash equivalents deconsolidated   (210)
Net cash used in investing activities upon deconsolidation   (210)

 

24

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 9 – CREDIT FACILITY

 

On October 1, 2024, the Company entered into a facility agreement with L.I.A. Pure Capital Ltd. (the “Lender”) for financing of up to €6,000 thousand (approximately $7,020) (the “Pure Capital Credit Facility”), of which €2,000 thousand (approximately $2,340) may be used for the Loan and Partnership Agreement in Germany, and the remaining €4,000 thousand (approximately $4,680) for other pre-approved projects. The facility bears annual interest of 7%, payable in advance and deducted from each drawdown, for a period of 24 months.

 

On May 27, 2026, the Company and the Lender released from escrow the signatures to an amended and restated facility agreement (the “Amended Facility Agreement”), which amended and restated the Original Facility Agreement in its entirety. The Amended Facility Agreement increased the maximum amount available under the Pure Capital Credit Facility from €6,000 thousand to €10,000 thousand and revised the permitted use of the proceeds to finance the Company’s operations and potential transactions, including acquisitions, subject to the Lender’s prior approval of each drawdown.

 

The facility will expire upon full drawdown or five years from the agreement date, whichever occurs first. Borrowed amounts are to be repaid from project proceeds or 33% of proceeds from other Company financings during the drawdown period. As of September 30, 2026, aggregate drawdowns under the Pure Capital Credit Facility amounted to approximately €1,249 thousand (approximately $1,340) and aggregate repayments amounted to approximately €1,015 thousand (approximately $1,165), such that the outstanding principal amounted to approximately €234 thousand (approximately $271). During the nine months ended September 30, 2026, the Company did not make any additional drawdowns or repayments under the Pure Capital Credit Facility.

 

In connection with the Pure Capital Credit Facility, the Company issued a five-year warrant to the Lender. In accordance with the anti-dilution provisions of the warrant agreement and following the Company’s entry into the PIPE Agreement, the exercise price of the warrant was adjusted during 2025. As adjusted to reflect the April Reverse Stock Split and the November Reverse Stock Split, immediately prior to the execution of the Amended Facility Agreement, the warrant was exercisable for 1,511 shares of Common Stock at an exercise price of $122.5 per share.

 

Under the Amended Facility Agreement, the terms applicable to the warrant were amended such that the warrant became exercisable for 370,000 shares of Common Stock at an exercise price of $5.00 per share. Prior to September 29, 2026, the Amended Facility Agreement also provided that, upon certain dilutive issuances that reduced the warrant exercise price, the Company was required to issue an additional warrant to maintain the aggregate exercise price. This provision was deleted effective September 29, 2026, as described below.

 

Prior to September 29, 2026, the Company determined that, due to certain anti-dilution provisions, the warrant was not indexed to the Company’s own stock and, accordingly, was accounted for as a liability measured at fair value at each reporting date. Changes in fair value are recognized in the consolidated statements of operations until reclassification on September 29, 2026.

 

On September 29, 2026, the Company and the Lender entered into an agreement to amend and restate the warrant, effective on that date. The amended and restated warrant superseded and replaced the previously outstanding warrant and removed certain provisions that had resulted in liability classification. In addition, a provision of the amended facility agreement requiring the Company, following a dilutive issuance resulting in a reduction of the warrant’s exercise price, to issue an additional warrant to the Lender covering a number of shares calculated to preserve the aggregate exercise price payable prior to such issuance was eliminated. The amendment did not increase the number of shares issuable upon exercise of the warrant, extend its term or otherwise provide additional economic consideration to the Lender.

 

25

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 9 – CREDIT FACILITY (continued)

 

Following the amendments, the Company reassessed the warrant under ASC 815-40 and concluded that it qualified for equity classification. Immediately prior to reclassification on September 29, 2026, the Company remeasured the warrant liability to its fair value of $2,414 and recognized a gain of $5,171 from the change in fair value in finance income during the three months ended September 30, 2026. The remaining warrant liability of $2,414 was reclassified to additional paid-in capital.

 

The Company estimated the fair value of the warrant liability as of September 29, 2026 (immediately prior to its reclassification), and December 31, 2025, using the Black-Scholes option pricing model.

 

The assumptions used to perform the calculations are detailed below:

 

  

Fair value of warrant liability 

September 29,

2026

  

December 31,

2025

 
Expected volatility (%) (*)   169.84%   152.35%
Risk-free interest rate (%)    5.02%   3.73%
Expected dividend yield   0.0%   0.0%
Expected term of warrants (years)   4.00    4.75 
Exercise price (US dollars)  $5.00   $122.5 
Share price (US dollars)  $7.00   $58.80 
Fair value (U.S. dollars)  $2,414   $78 

 

(*)The expected volatility was based on the historical volatility of the share price of the Company.

 

On October 7, 2026, subsequent to the balance sheet date, the Lender exercised a portion of the warrants issued, resulting in aggregate cash proceeds to the Company of approximately $552 thousand. See Note 14 – Subsequent Events for additional information.

 

The Company elected to account for the loans drawn under the Pure Capital Credit Facility under the fair value option in accordance with ASC 825.

 

As of September 30, 2026, the Company reassessed the fair value of the outstanding loans based on the contractual repayment provisions and the financing transactions completed during the period. As a result of these financing transactions, the Lender became entitled to repayment of the outstanding loan balance. Accordingly, the Company determined that the fair value of the loans approximated the outstanding principal and accrued interest, amounting to approximately $279 as of September 30, 2026.

 

26

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 10 – COMMON STOCK AND WARRANTS

 

1.On January 2, 2025, the Company consummated a Private Placement transaction contemplated by the securities purchase agreement, dated December 10, 2024, and issued 1,392 shares; pre-funded warrants to purchase 3,711 shares; and warrants to purchase 7,654 shares of the Company’s common stock at an exercise price of $394. The Company received gross proceeds of $1,500 as a result of such issuances.

 

The number of shares, pre-funded warrants and warrants, as well as the exercise prices presented in this note, have been adjusted to reflect the 1-for-7 reverse stock split effected on April 8, 2026 and 1-for-5 reverse stock split on November 9, 2026.

 

The Company considered the guidelines of ASC 815 and determined that the warrants issued in Private Placement meet the definition of a liability and were therefore classified as warrant liabilities in the balance sheet. The pre-funded warrants were classified as equity.

 

During 2025, certain holders exercised their warrants, and the Company remeasured the related warrant liabilities through the respective exercise dates. During the nine months ended September 30, 2026, there were no exercises of warrants.

 

The warrant liabilities are measured at fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations.

 

The fair value of the warrant liabilities was determined using a Black-Scholes option pricing model. The assumptions used to perform the calculations are detailed below:

  

Month 

Expected

volatility

(%) (*)

  

Risk free

interest

rate

  

Expected

dividend

yield

  

Expected

term of

options

(years)

  

Exercise

price (US

dollars)

  

Share

price (US

dollars)

  

Fair

value (U.S.

dollars)

 
September 30, 2026   167.78%   5.05%   0.0%   3.75   $182   $6.95   $10 

 

(*)The expected volatility was based on the historical volatility of the share price of the Company.

 

2.On May 12, 2025, the Company, entered into a Purchase Agreement (the “Agreement”) with YA II PN, Ltd. (the “Investor”) as part of the Standby Equity Purchase Agreement dated as of December 22, 2023 (the “SEPA II”).

 

On August 12, 2025, pursuant to the Purchase Agreement, the Company issued a promissory note in the principal amount of $1,500 to the Investor. The note bears interest at 8% per annum and matures 12 months from issuance. As the SEPA II had an initial fair value of zero at inception, no amounts were allocated to this component. Accordingly, all transaction costs associated with the Purchase Agreement were attributed to the promissory note and recorded as deferred financing costs, presented as a direct deduction from the carrying amount of the note payable and amortized to financing expense over its term using the effective interest method. During the nine months ended September 30, 2026, the Company repaid $1,200 of the outstanding promissory note and recognized financing expenses of $460 related to the promissory note, including the amortization of deferred financing costs. As of September 30, 2026, the promissory note had been fully repaid, and no outstanding balance remained.

 

On January 22, 2026, the Company issued 39,636 shares of Common Stock pursuant to the terms of the SEPA II. The shares were valued at $2,511, and the Company received net proceeds of $2,896, after a 6% discount from gross consideration of $3,081. In connection with this issuance, the Company recorded other income in the amount of $386 in the consolidated statements of operations. Following this issuance, the Company issued the full amount under the registration statement on Form S-1 declared effective on August 22, 2025.

 

27

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 10 – COMMON STOCK AND WARRANTS (continued)

 

3.On January 8, 2026, the Company issued 1,000 shares of common stock pursuant to a new consulting agreement to a consultant in consideration of investor relations services provided to the Company. The Company estimated the value of the shares issued at $57 based on the share price of the date of the board resolution of which $42 and $14 was recorded as share-based compensation expenses during the nine and three months ended September 30, 2026, respectively and the remaining $15 was recorded as prepaid expenses.

 

4.On February 9, 2026, the board of directors of the Company approved the issuance of an equity grant to executive officers, Company’s chairman of the board and consultant amounting to a total of 9,039 shares of common stock. The Company estimated the value of the shares issued at $323 based on the share price of the date of the board resolution. The value of the shares issued was recorded as share base compensation expenses during the nine months ended September 30, 2026.

 

5.On February 23, 2026, the Company issued an aggregate of 17,145 shares of common stock outside of the Plan to three consultants, pursuant to board resolution, dated February 20, 2026. The Company estimated the value of the shares issued at $558 based on the share price of the date of the board resolution. The value of the shares issued was recorded as share base compensation expenses during the nine months ended September 30, 2026.

 

6.On June 12, 2026, the Company entered into a securities purchase agreement with certain investors pursuant to which the Company issued and sold 62,379 shares of Common Stock in a registered direct offering and warrants to purchase up to 62,379 shares of Common Stock in a concurrent private placement (the “First PIPE Warrants”) at a combined purchase price of $20.04 per share and accompanying First PIPE Warrant. The Company received gross proceeds of approximately $1,250 from the transaction, which closed on June 15, 2026.

 

The First PIPE Warrants had an initial exercise price of $20.04 per share and became exercisable on June 15, 2026. Prior to their amendment on September 29, 2026, the First PIPE Warrants contained certain anti-dilution provisions, including provisions that could adjust the exercise price and the number of shares issuable upon exercise in connection with certain share combination events and future dilutive issuances.

 

The Company considered the guidance in ASC 815-40 and determined that, prior to their amendment, the First PIPE Warrants were not indexed to the Company’s own stock. Accordingly, the First PIPE Warrants were classified as liabilities and are remeasured at fair value at each reporting date through September 29, 2026, with changes in fair value recognized in the Condensed Consolidated Statements of Operations.

 

28

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 10 – COMMON STOCK AND WARRANTS (continued)

 

The fair value of the First PIPE Warrants liabilities at initial recognition, and on September 29, 2026 (immediately prior to its reclassification), was determined using a Black-Scholes option pricing model under probability-weighted scenarios reflecting the anti-dilution provisions then in effect. The assumptions used in the valuations are detailed below:

 

Fair value of First PIPE Warrants liabilities 

September 29,

2026

  

June 15,

2026

 
Expected volatility (%) (*)   156.01%   158.75%
Risk-free interest rate (%)   5.09%   4.18%
Expected dividend yield   0.0%   0.0%
Expected term of warrants (years)   4.25-4.71    4.5-5 
Contractual exercise price (US dollars)  $20.04   $20.04 
Potential adjusted exercise price range (US dollars)  $

2.5-$20

   $2.5-$20 
Share price (US dollars)  $7.00   $27.70 
Fair value (U.S. dollars)  $909   $2,162 

 

(*)The expected volatility was based on the historical volatility of the share price of the Company.

 

The fair value of the First PIPE Warrants liabilities upon initial recognition on June 15, 2026 was approximately $2,162. As the initial fair value of the First PIPE Warrants liabilities exceeded the gross proceeds received in the transaction, the Company recognized a loss upon initial recognition of approximately $912.

 

On September 29, 2026, the Company entered into amendments to the First PIPE Warrants, which removed certain provisions that previously resulted in liability classification. Following these amendments, the Company determined that the First PIPE Warrants met the requirements for equity classification under ASC 815-40.

 

Immediately prior to reclassification, the Company remeasured the First PIPE Warrants liabilities to their fair value of approximately $909, recognizing a gain of approximately $877 during the three months ended September 30, 2026, and a cumulative gain of approximately $1,253 from subsequent fair value remeasurement during the nine months ended September 30, 2026.

 

The Company subsequently reclassified the warrant liabilities of $909 to additional paid-in capital. Accordingly, no liability related to the First PIPE Warrants remained outstanding as of September 30, 2026.

 

29

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 10 – COMMON STOCK AND WARRANTS (continued)

 

7.On June 22, 2026, the Company entered into a securities purchase agreement with certain investors pursuant to which the Company issued and sold 82,204 shares of Common Stock in a registered direct offering and warrants to purchase up to 82,204 shares of Common Stock in a concurrent private placement (the “Second PIPE Warrants”) at a combined purchase price of $35.28 per share and accompanying Second PIPE Warrant. The Company received gross proceeds of approximately $2,900 from the transaction, which closed on June 23, 2026.

 

The Second PIPE Warrants had an initial exercise price of $35.28 per share and became exercisable on June 24, 2026. Prior to their amendment on September 29, 2026, the Second PIPE Warrants contained certain anti-dilution provisions, including provisions that could adjust the exercise price and the number of shares issuable upon exercise in connection with certain share combination events and future dilutive issuances.

 

The Company considered the guidance in ASC 815-40 and determined that, prior to their amendment, the Second PIPE Warrants were not indexed to the Company’s own stock. Accordingly, the Second PIPE Warrants were classified as liabilities and are remeasured at fair value at each reporting date through September 29, 2026, with changes in fair value recognized in the Condensed Consolidated Statements of Operations.

 

The fair value of the Second PIPE Warrants liabilities at initial recognition, and on September 29, 2026 (immediately prior to its reclassification), was determined using a Black-Scholes option pricing model under probability-weighted scenarios reflecting the anti-dilution provisions of the Second PIPE Warrants. The assumptions used in the valuations are detailed below:

 

Fair value of Second PIPE Warrants liabilities  September 29, 2026   June 24, 2026 
Expected volatility (%) (*)   156.01%   158.31%
Risk-free interest rate (%)    5.09%   4.17%
Expected dividend yield   0.0%   0.0%
Expected term of warrants (years)   4.25-4.73    4.5-5 
Contractual exercise price (US dollars)  $35.28   $35.28 
Potential adjusted exercise price range (US dollars)  $2.5-$32.5   $2.5-$32.5 
Share price (US dollars)  $7.00   $29.65 
Fair value (U.S. dollars)  $2,266   $4,053 

 

(*)The expected volatility was based on the historical volatility of the share price of the Company.

 

The fair value of the Second PIPE Warrants liabilities upon initial recognition on June 24, 2026 was approximately $4,053. As the initial fair value of the Second PIPE Warrants liabilities exceeded the gross proceeds received in the transaction, the Company recognized a loss upon initial recognition of approximately $1,153.

 

30

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 10 – COMMON STOCK AND WARRANTS (continued)

 

On September 29, 2026, the Company entered into amendments to the Second PIPE Warrants, which removed certain provisions that previously resulted in liability classification. Following these amendments, the Company determined that the Second PIPE Warrants met the requirements for equity classification under ASC 815-40.

 

Immediately prior to reclassification, the Company remeasured the Second PIPE Warrants liabilities to their fair value of approximately $2,266, recognizing a gain of approximately $1,147 during the three months ended September 30, 2026, and a cumulative gain of approximately $634 from subsequent fair value remeasurement during the nine months ended September 30, 2026.

 

The Company subsequently reclassified the warrant liabilities of $2,266 to additional paid-in capital. Accordingly, no liability related to the Second PIPE Warrants remained outstanding as of September 30, 2026.

 

8.On August 31, 2026, the Company issued 6,978 shares of common stock to the former shareholders of MitoCareX Bio Ltd. in connection with the achievement of the first milestone under the acquisition agreement. See Note 3 for additional details.

 

9.During the nine months ended September 30, 2026, the Company recorded share base compensation expenses in General and Administrative expenses in the amount of $498 related to shares issued by the Company to service providers by December 31, 2025.

 

NOTE 11 – STOCK OPTIONS AND RESTRICTED STOCK UNITS

 

The following table presents the Company’s stock option activity under its equity incentive plans for the nine months ended September 30, 2026:

  

  

 

Number of Options

   Weighted Average Exercise Price 
Outstanding at December 31, 2025   23    17,719.24 
Granted   -    - 
Exercised   -    - 
Forfeited or expired   (13)   11,582.09 
Outstanding at September 30, 2026   10    29,172.15 
Number of options exercisable at September 30, 2026   10    29,172.15 

 

During the nine months ended September 30, 2026, following the sale of Save Foods Ltd., a former subsidiary of the Company, certain options previously granted to employees of Save Foods Ltd. were forfeited in accordance with the terms of the applicable awards.

 

The aggregate intrinsic value of the awards outstanding as of September 30, 2026, was $0. These amounts represent the total intrinsic value, based on the Company’s stock price of $6.95 as of September 30, 2026, less than the weighted exercise price.

 

On October 20, 2025, the Company granted 4,186 restricted stock units (“RSUs”) to Mr. Alon Silberman under the Company’s 2022 Share Incentive Plan. The RSUs vest in three equal annual installments on each of the first, second and third anniversaries of the grant date, subject to continued employment with MitoCareX.

 

31

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 11 – STOCK OPTIONS AND RESTRICTED STOCK UNITS (continued)

 

On September 23, 2026, the Company entered into an RSU Cancellation and Cash Settlement Agreement with Mr. Silberman, pursuant to which all outstanding RSUs, whether vested or unvested, were cancelled, in consideration for a one-time cash payment of $30.

 

In accordance with ASC 718, the Company accelerated the recognition of the remaining unrecognized compensation cost. As the cash consideration did not exceed the fair value of the RSUs at the settlement date, the payment was recorded as a reduction of additional paid-in capital, and no incremental compensation expense was recognized in connection with the cash settlement.

 

Costs incurred in respect of stock-options and RSUs compensation for employees and directors for the nine and three months ended September 30, 2026 were $377 and $217, respectively, including the accelerated compensation expense resulting from the cancellation of the RSUs.

 

NOTE 12 – RELATED PARTIES

 

A.Transactions and balances with related parties

  

   2026   2025 
   Nine months ended September 30 
   2026   2025 
General and administrative expenses:          
Directors’ compensation   476    324 
Salaries and fees to officers   784    856 
Total General and administrative expenses   (*)1,260   (*)1,180
           
(*) of which share based compensation   404    533 
           
Research and development expenses:          
Salaries and fees to officers   704    - 
    (*)704   - 
           
(*) Includes share-based compensation   326    - 

 

(*)
  B. Balances with related parties and officers:

 

   As of September 30,   As of December 31, 
   2026   2025 
           
Other accounts payables   404    146 

 

32

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 13 – SEGMENT REPORTING

 

A.Information about reported segment of profit or loss and assets

 

As of September 30, 2026, the Company has two reportable segments: (i) Biotechnology activity, and (ii) Renewable energy projects. The Biotechnology operating segment consists of MitoCareX from the acquisition date, and the Renewable energy projects operating segment consists of NITO Renewable Energy, Inc. and Solar photovoltaic joint venture project.

 

The CODM evaluates performance and allocates resources based primarily on segment operating loss. Prior period segment information has been recast to conform to the current year presentation.

 

The following table presents information about the Company’s reportable segments for the nine and three months ended September 30, 2026, and 2025:

  

   2026   2025   2026   2025 
   Nine months ended   Three months ended 
   September 30   September 30 
   2026   2025   2026   2025 
                 
Revenue from biotechnology activity   -    -    -    - 
Cost related to biotechnology activity (*)   (458)   -    (120)   - 
Salaries and related expenses related to biotechnology activity   (627)   -    (161)   - 
Amortization of intangible asset   (305)   -    (103)   - 
Operating loss from Biotechnology activity   (1,390)   -    (384)   - 
                     
Revenue from renewable energy projects   -    -    -    - 
Cost related to renewable energy projects   (20)   (263)   (1)   (133)
Operating loss from renewable energy projects   (20)   (263)   (1)   (133)
                     
Professional services   (1,150)   (1,029)   (234)   (472)
Share base compensation   (1,828)   (2,141)   (429)   (112)
Change in fair value of contingent consideration   349    -    146    - 
Goodwill impairment   (6,291)   -    -    - 
Depreciation   (11)   -    (4)   - 
Other general and administrative expenses   (994)   (768)   (328)   (354)
Total Operating loss   (11,335)   (4,201)   (1,234)   (1,071)
                     
Interest of loans   (26)   (77)   (3)   - 
Financing expenses, net   (1,844)   (1,778)   7,070    174 
Other income   386    1,662    -    1,662 
Changes in fair value of investments measured under the fair value option   (832)   (493)   (855)   (149)
Net gain (loss) before tax   (13,651)   (4,887)   4,978    616 
Income taxes   70    -    24    - 
Net gain (loss)   (13,581)   (4,887)   5,002    616 

 

(*)Costs related to biotechnology activity primarily consist of subcontractors engaged in research and development activities

 

33

 

 

NEXENTIS TECHNOLOGIES INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

(USD in thousands, except share and per share data)

 

NOTE 14 – SUBSEQUENT EVENTS

 

1.On October 7, 2026, the Lender exercised warrants issued in connection with the Pure Capital Credit Facility for an aggregate cash consideration of approximately $552 thousand. The exercise is related to 110,337 shares of Common Stock at an exercise price of $5.00 per share. Following the exercise, the warrant remains exercisable for 259,663 shares of Common Stock. See Note 9 for additional information.

 

2.On October 15, 2026, the Company issued (i) 10,200 shares of common stock to a consultant for accounting and controller services provided to the Company; (ii) 20,310 shares of its common stock to David Palach, its Chief Executive Officer; (iii) 10,200 shares of common stock to Lital Barda, its Chief Financial Officer; (iv) an aggregate of 41,728 shares of common stock to the Company’s directors, in each case under its 2022 Share Incentive Plan (the “Plan”); and (v) an aggregate of 102,000 shares of common stock outside of the Plan to consultants in consideration of various financial, investor relations and business development services provided to the Company, for a total of 184,438 shares of common stock.

 

3.On October 26, 2026, the Company issued 2,000 shares of common stock pursuant to a new consulting agreement to a consultant in consideration of general consulting services and introductions to potential investors.
   
4.On November 9, 2026, the Company effected a 1-for-5 reverse stock split of its outstanding shares of common stock. As a result of the reverse stock split, every five shares of the Company’s issued, and outstanding common stock were automatically combined and reclassified into one share of common stock. No fractional shares were issued in connection with the reverse stock split, and fractional shares were rounded to the nearest whole number. The authorized number of shares of common stock and the par value per share remained unchanged.
  All share, stock option, warrants and per share information presented in these consolidated financial statements has been retroactively adjusted to reflect the reverse stock split for all periods presented. See also Note 1B.

 

  5. On November 9, 2026, the Company issued an aggregate of 72,000 shares of common stock to three consultants in consideration of investor relations and business development services to be provided over a 12-month period, pursuant to consulting agreements, dated November 9, 2026.

 

34

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and related notes included elsewhere in this Quarterly Report. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. See “Forward-Looking Statements” for a discussion of the uncertainties and assumptions associated with these statements. Our actual results may differ materially from those discussed below.

 

All information in this Quarterly Report relating to shares or price per share reflects the 1-for-35 reverse stock split effected by us on September 22, 2025 and the 1-for-7 reverse stock split effected by us on April 8, 2026 and the 1-for-5 reverse stock split effected by us on November 9, 2026.

 

Overview

 

We are focused on sustainable operations in various industries such as oncology biotechnology and solar projects. Our activities are advancing innovative oncology solutions through MitoCareX to improve cancer treatment outcomes.

 

We currently operate through our wholly owned Israeli subsidiary and our Nevada wholly-owned subsidiary and collaborate and invest in a joint venture in the solar energy sector:

 

MitoCareX, which has been our wholly owned subsidiary since October 2025, develops and advances targeted therapeutics for diverse types of indications by focusing on transport proteins (i.e., transporters). MitoCareX develops technologies that are designed to interact with transporters, thereby potentially disrupting the disease. MitoCareX routinely utilizes structural biology in combination with computational chemistry to discover, design and develop drug candidates that interact with its protein targets of interest. MitoCareX’s approach leverages a proprietary MITOLINE™ algorithm, which enables the reliable generation of 3D molecular structural models of MitoCareX’s protein targets and allows for large-scale virtual screening campaigns against these targets. MITOLINE™ provides a platform-level starting point to enable modelling and further allows to discover potential therapeutics. A key advantage of MitoCareX platform is its ability to address the historical lack of experimental structural data that has limited drug discovery efforts targeting MitoCareX’s proteins of interest, thereby potentially expanding the druggable target space. By enabling rational, structure-guided discovery at scale, MitoCareX’s solutions are designed to unlock new treatment opportunities. Recently, MitoCareX entered into an engagement with Boltz, PBC (“Boltz”), an AI research lab that focuses on biomolecular foundation models and drug discovery workflows, to accelerate the identification of potential therapeutics targeting selected proteins of interest to MitoCareX’s pipeline. In October 2026, MitoCareX completed an initial computational screening stage under this initiative.

 

We collaborate with Solterra Renewable Energy Ltd., an Israeli corporation (“Solterra”) and a former wholly-owned subsidiary of Solterra Energy Ltd., an Israeli public corporation, listed on the Tel Aviv Stock Exchange (“Solterra Energy”), which operates in the solar energy sector and presents certain investment opportunities in solar photovoltaic (“PV”) projects. Solterra engages in the development of renewable energy projects through its subsidiaries. Currently, operations are conducted in Italy, Poland, and Germany, with potential expansion to additional countries. Our subsidiary, NITO Renewable, was established in February 2025 in the State of Nevada and has a 70% interest in the joint venture in Italy. Solterra’s business strategy primarily involves selling renewable energy projects to third parties at various stages of development, from the initial land identification and project advancement through construction, operation, or sale to a third party. Currently, most projects are expected to be sold at various development stages, with the possibility of a larger portion of projects being held long-term for operation by Solterra in the future. In July 2026, Solterra Energy completed the sale of 100% of the issued share capital of Solterra to Sunflower Sustainable Investments Ltd., an Israeli public corporation listed on the Tel Aviv Stock Exchange. We currently intend to continue to collaborate with Solterra as Solterra surveys the European solar energy market for additional projects.

 

35

 

 

During 2025, the Company underwent significant changes to its business operations. In April 2025, the Company completed the sale of its NTWO OFF Ltd. operations. In addition, during 2025, the Company classified the operations of Save Foods Ltd., our former 98.48% owned subsidiary (“Save Foods”), as held for sale and discontinued operations. Accordingly, the results of these operations are presented separately in the consolidated financial statements and are not included in the discussion of continuing operations below.

 

As a result of these changes, the Company’s consolidated financial statements for the periods presented have been reclassified to conform to the current presentation, and therefore may not be directly comparable to prior periods. Unless otherwise indicated, the discussion below relates to the Company’s continuing operations.

 

On January 13, 2026, we entered into a Securities Exchange Agreement (the “SF Agreement”) with Voice Assist, Inc., a public company incorporated under the laws of the State of Nevada (“Voice Assist”), and, for certain limited purposes set forth therein, Save Foods. On January 13, 2026, we also entered into a Services Agreement with Voice Assist (the “Services Agreement”), pursuant to which we will provide non-exclusive general advisory, support, collaboration and related services to Voice Assist from time to time for consideration consisting of deferred cash from future Voice Assist financings (subject to a $1,000,000 cap), royalty consideration on “New Future Projects” (as defined in the Services Agreement) over specified periods, and a share of any “Ecolab Gross Proceeds” (as defined in the Services Agreement) related to the Ecolab Claim, and the Services Agreement includes successor obligations with respect to royalty consideration and a term through calendar year 2026 with the Company’s extension rights until consideration is fully received. On March 15, 2026, we closed the SF Agreement (the “Closing”). At the Closing, we transferred to Voice Assist all of the ordinary shares of Save Foods owned by us, representing approximately 98% of the issued and outstanding ordinary share capital of Save Foods, free and clear of any encumbrances and Voice Assist delivered to us number of shares of common stock of Voice Assist, par value $0.001 per share, that represented 19.99% of Voice Assist shares of common stock.

 

We currently own 19.99% of Voice Assist.

 

Additionally, we currently own approximately 8.2% of Plantify Foods Inc. (“Plantify”), a Canadian-based public company listed on the TSX Venture Exchange that was previously engaged in the food tech industry primarily through its Israeli subsidiary, Piece of Bean Ltd. (“Piece of Bean”), which was involved in the production and distribution of clean label food. Piece of Bean’s factory and business operations, located in Kibbutz Gonen in the Golan Heights, were severely impacted by the recent war in Israel, and Piece of Bean is in the process of voluntary insolvency proceedings. As a consequence, Plantify currently has essentially no business activity and minimal liquidity.

 

Recent Developments

 

Nasdaq Listing Compliance

 

On August 31, 2026, we received a letter (the “Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that our stockholders’ equity of $1,782,000, as reported in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, was below the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2,500,000. The Letter had no immediate impact on the listing or trading of our common stock on The Nasdaq Capital Market. Pursuant to the Letter, we had 45 calendar days, or until October 15, 2026, to submit a plan to regain compliance and, if such plan is accepted, the Listing Qualifications Staff may grant an extension of up to 180 calendar days from the date of the Letter, or through February 27, 2027, to evidence compliance. On October 10, 2026, we submitted a plan to regain compliance to the Listing Qualifications Staff.

 

36

 

 

On September 29, 2026, we entered into amendment agreements (the “Amendment Agreements”) with the holders of all outstanding warrants issued in connection with (i) our credit facility with L.I.A. Pure Capital Ltd., originally entered into on October 1, 2024 and amended and restated in May 2026, (ii) our concurrent private placement conducted alongside our registered direct offering that closed on June 15, 2026 and (iii) our concurrent private placement conducted alongside our registered direct offering that closed on June 24, 2026 (collectively, the “Existing Warrants”). Pursuant to the Amendment Agreements, the parties agreed to amend the Existing Warrants and enter into amended and restated warrants (the “Amended Warrants” and, together with the Amendment Agreements, the “Amendments”). The Amended Warrants removed certain provisions contained in the Existing Warrants that resulted in liability classification for accounting purposes, and we determined that the Amended Warrants qualify for equity classification under applicable accounting guidance. The Amendments did not increase the number of shares issuable upon exercise of the Existing Warrants, extend their terms or otherwise provide additional economic consideration to the holders thereof, and were effected in connection with our efforts to regain compliance with Nasdaq Listing Rule 5550(b)(1). As a result of the Amendments and the non-cash financing income recognized during the third quarter of 2026, our reported stockholders’ equity as of September 30, 2026 was $12,774,000, which exceeded the minimum requirement of $2,500,000. However, Nasdaq will continue to monitor our compliance with the stockholders’ equity requirement, and there can be no assurance that Nasdaq will determine that we have regained compliance, that we will be able to maintain compliance with Nasdaq Listing Rule 5550(b)(1) or any other continued listing requirement, or that our common stock will not be delisted.

 

Subsequent Equity Issuances and Warrant Exercises

 

On October 7, 2026, we issued 110,337 shares of common stock upon the exercise of outstanding warrants.

 

On October 15, 2026, we issued an aggregate of 184,438 shares of common stock to our directors, executive officers and consultants in consideration of services provided to the Company. Of these shares, 82,438 were issued pursuant to the Company’s 2022 Share Incentive Plan to our Chief Executive Officer, our Chief Financial Officer, our directors and a consultant, while the remaining 102,000 shares were issued to consultants outside the plan for financial, investor relations and business development services.

 

On October 26, 2026, we issued an additional 2,000 shares of common stock to a consultant in consideration of services provided to the Company.

 

2026 Annual Meeting and Proposed Convertible Note Financing Facility

 

On November 9, 2026, we filed a preliminary proxy statement with the SEC for our 2026 annual meeting of stockholders, scheduled to be held on December 30, 2026, at which our stockholders will be asked, among other things, to approve, for purposes of Nasdaq Listing Rule 5635(d), (i) the issuance of up to 20,000,000 shares of common stock (subject to adjustment for any reverse stock split effected prior to such offerings), for aggregate consideration of up to $100 million, in one or more non-public offerings at a maximum discount of 20% below the market price of our common stock, and (ii) the potential issuance of shares of common stock pursuant to a proposed convertible note financing facility with a single investor, under which we may issue unsecured convertible promissory notes in an aggregate principal amount of up to $10 million, together with warrants and shares issuable as a commitment fee.

 

We have negotiated with a single investor (the “Investor”) the material terms of a proposed convertible note financing facility. We and the Investor have not yet entered into definitive agreements with respect to the proposed financing. We presently intend to enter into definitive agreements with the Investor following receipt of the stockholder approval sought pursuant to this Proposal, substantially on the terms described below. The proposed definitive agreements are expected to consist of a Securities Purchase Agreement (the “Purchase Agreement”), unsecured convertible promissory notes to be issued thereunder (the “Notes”) and warrants to purchase shares of our common stock to be issued in connection with each Note (the “Warrants,” and together with the Purchase Agreement and the Notes, the “Transaction Documents”). The shares of common stock issuable upon conversion of the Notes are referred to as the “Conversion Shares,” the shares of common stock issuable upon exercise of the Warrants are referred to as the “Warrant Shares,” and the shares of common stock proposed to be issued as a commitment fee are referred to as the “Commitment Shares.”

 

37

 

 

Under the proposed Purchase Agreement, we would be permitted to issue and sell to the Investor, from time to time, Notes in an aggregate principal amount of up to $10 million. Upon execution of the Purchase Agreement (the “Initial Closing”), the Investor would purchase from us a Note in the principal amount of $1,500,000 for a purchase price of $1,350,000. Commencing on January 1, 2027, we would be permitted to request, in our sole discretion, that the Investor purchase additional Notes, with the aggregate principal amount of Notes issued during each calendar quarter not to exceed $1,500,000. Each Note would be issued at a purchase price equal to 90% of its principal amount, reflecting a 10% original issue discount.

 

Each Note would mature 28 months after its issuance date and would bear interest at an annual rate of 8%, which would increase to 14% upon an event of default for so long as the event remains uncured. The principal amount of each Note, together with accrued and unpaid interest, would be payable in 10 equal monthly installments beginning on the first day of each month following the 18-month anniversary of the applicable issuance date, unless repaid earlier in accordance with the Note or the maturity date is extended at the option of the Investor.

 

The outstanding amounts due under each Note would be convertible into shares of our common stock at the option of the Investor at any time after the issuance date of the Note at a conversion price per share equal to the lower of (i) the closing price of our common stock on the trading day immediately preceding the date on which our stockholders approve this Proposal (the “Fixed Price”), and (ii) 88% of the lowest daily volume-weighted average price of our common stock during the 20 consecutive trading days immediately preceding the applicable conversion date, provided that the variable conversion price per share may not be lower than 20% of the Fixed Price (the “Floor Price”), subject to certain adjustments as provided in the Note. The Investor’s right to convert a Note would be subject to the limitation that a conversion may not result in the Investor and its affiliates beneficially owning more than 4.99% of our outstanding common stock.

 

At each closing under the Purchase Agreement, we would also issue to the Investor a Warrant to purchase a number of shares of common stock equal to 100% of the Conversion Shares underlying the Note issued at that closing, determined by dividing the principal amount of the applicable Note by the variable conversion price then in effect. Each Warrant would have an exercise price per share equal to 80% of the Fixed Price and would expire 60 months after issuance, in each case subject to adjustment as provided in the Warrant. The Investor’s right to exercise a Warrant would also be subject to a 4.99% beneficial ownership limitation.

 

In consideration for the Investor’s execution and delivery of the Purchase Agreement, at the Initial Closing we would issue to the Investor a number of Commitment Shares equal to 4.99% of the number of shares of our common stock outstanding immediately after giving effect to such issuance.

 

Under the proposed Purchase Agreement, we would be required to prepare and file with the Securities and Exchange Commission, as soon as practicable but no later than 30 trading days after execution of the Purchase Agreement, a resale registration statement covering the Conversion Shares, the Warrant Shares and the Commitment Shares, and to use reasonable best efforts to cause the registration statement to become effective within the period specified in the Purchase Agreement.

 

If a Nasdaq rule establishing a minimum Market Value of Listed Securities requirement of at least $5.0 million for companies listed on the Nasdaq Capital Market becomes effective while any portion of a Note remains outstanding, from and after the effectiveness of such rule, the conversion price under the Notes would be equal to the lower of (i) the Fixed Price and (ii) 50% of the lowest daily volume-weighted average price of our common stock during the 20 consecutive trading days immediately preceding the applicable conversion date, subject to the Floor Price.

 

Because definitive agreements have not yet been executed, there can be no assurance that the proposed financing will be consummated. If definitive agreements are executed, we expect that the material terms of the financing will be substantially as described in this Proposal. If definitive agreements are executed, the foregoing descriptions will be qualified in their entirety by reference to the full text of the Transaction Documents, which we expect to file with the SEC as required by applicable law.

 

In addition to the proposals described above, at the 2026 annual meeting, our stockholders will also be asked, among other things, to approve an amendment to our 2022 Share Incentive Plan to increase the number of shares of common stock available for issuance thereunder by an additional 1,000,000 shares of common stock. 

 

38

 

 

Results of Operations

 

The 2025 comparative amounts presented below have been recast to reflect the classification of the Company’s Save Foods and NTWO OFF Ltd. operations as discontinued operations. Accordingly, the results of these discontinued operations are excluded from continuing operations. Unless otherwise indicated, the discussion below relates only to the Company’s continuing operations.

 

Operating Expenses

 

Our current operating expenses consist of five components - research and development expenses, general and administrative expenses, change in fair value of contingent consideration, goodwill impairment and depreciation and amortization.

 

Research and Development Expenses

 

Our research and development expenses consist primarily of salaries and related expenses and other related research and development expenses such as field tests.

 

  

Nine Months Ended

September 30,

  

Three Months Ended

September 30,

 
U.S. dollars  2026   2025   2026   2025 
Salaries and related expenses   599,000    -    174,000    - 
Subcontractors   67,000    -    20,000    - 
Laboratory and Field tests   178,000    -    61,000    - 
Other expenses   92,000    -    33,000    - 
Total   936,000    -    288,000    - 

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of professional services, share based compensation and other non-personnel related expenses.

 

  

Nine Months Ended

September 30,

  

Three Months Ended

September 30,

 
U.S. dollars  2026   2025   2026   2025 
Professional services   1,763,000    1,645,000    429,000    777,000 
Share based compensation   1,828,000    2,141,000    429,000    112,000 
Salaries and related expenses   115,000    -    19,000    - 
Legal expenses   231,000    233,000    36,000    130,000 
Insurance   94,000    106,000    32,000    32,000 
Registration fees   54,000    61,000    15,000    18,000 
Other expenses   56,000    15,000    25,000    2,000 
Total   4,141,000    4,201,000    985,000    1,071,000 

 

Three months ended September 30, 2026 compared to three months ended September 30, 2025

 

Research and Development Expenses

 

Research and development expenses consist of salaries and related expenses, service providers’ costs, related materials and overhead expenses. Research and development expenses for the three months ended September 30, 2026 were $288,000, compared to no research and development expenses for the three months ended September 30, 2025. The increase was attributable to research and development activities following the acquisition of MitoCareX in October 2025, including personnel-related expenses and costs associated with its ongoing development programs.

 

39

 

 

General and Administrative Expenses

 

General and administrative expenses consisted primarily of professional services, salaries and related expenses including share based compensation and other non-personnel related expenses, including legal expenses and directors and officers insurance costs. General and administrative expenses for the three months ended September 30, 2026 were $985,000, a decrease of $86,000, or 8%, compared to general and administrative expenses of $1,071,000 for the three months ended September 30, 2025. The decrease was primarily attributable to decrease of professional services and legal expenses, partially offset by an increase of share-based compensation to our employees and service providers.

 

Change in fair value of contingent consideration

 

Change in fair value of contingent consideration for the three months ended September 30, 2026 resulted in a non-cash gain of $146,000. The contingent equity consideration was recognized in connection with the acquisition of MitoCareX in October 2025 and is remeasured at fair value at each reporting date, with changes in fair value recognized in the statement of operations. The gain was primarily attributable to a decrease in the market price of the Company’s common stock during the period, which reduced the fair value of the liability associated with the contingent equity consideration.

 

Depreciation and amortization

 

Depreciation and amortization for the three months ended September 30, 2026 was $107,000, compared to no depreciation and amortization for the three months ended September 30, 2025. The increase was attributable to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX in October 2025 as part of the purchase price allocation.

 

Financing income, Net

 

Financing income, net for the three months ended September 30, 2026 was $7,067,000, an increase of $6,893,000 or 3,961%, compared to financing income, net of $174,000 for the three months ended September 30, 2025. The increase was primarily attributable to non-cash gains resulting from decreases in the fair value of the warrant liabilities associated with our credit facility with L.I.A. Pure Capital Ltd. and the warrants issued in the concurrent private placements that closed in June 2026, primarily due to a decrease in the market price of our common stock during the period. On September 29, 2026, we amended these warrants and, following their final remeasurement to fair value, the warrants were reclassified from liabilities to equity.

 

Income taxes

 

Income tax benefit for the three months ended September 30, 2026 was $24,000. The tax benefit is primarily attributable to a reduction in deferred tax liabilities, and does not reflect taxable income generated from operations. The decrease in deferred tax liabilities was primarily related to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX, which resulted in a corresponding income tax benefit.

 

Net gain from continuing operations

 

Net gain from continuing operations for the three months ended September 30, 2026, was $5,002,000, compared to $616,000 for the three months ended September 30, 2025, an increase of $4,386,000, or 712%. The increase was primarily attributable to higher financing income, net, as discussed above.

 

Net gain (loss) from discontinued operations

 

Net gain from discontinued operations for the three months ended September 30, 2026, was $17,000, compared to a net loss of $246,000 for the three months ended September 30, 2025. The gain in 2026 resulted from a post-closing adjustment related to the reconciliation of outstanding balances following the sale of Save Foods Ltd. in March 2026. The loss in 2025 reflected the operating results of the former Save Foods business.

 

Total net gain

 

As a result of the foregoing, our total net gain for the three months ended September 30, 2026 was $5,019,000 compared to $370,000 for the three months ended September 30, 2025, an increase of $4,649,000, or 1,256%.

 

40

 

 

Nine months ended September 30, 2026 compared to nine months ended September 30, 2025

 

Research and Development Expenses

 

Research and development expenses consist of salaries and related expenses, service providers’ costs, related materials and overhead expenses. Research and development expenses for the nine months ended September 30, 2026 were $936,000, compared to no research and development expenses for the nine months ended September 30, 2025. The increase was attributable to research and development activities following the acquisition of MitoCareX in October 2025, including personnel-related expenses and costs associated with its ongoing development programs.

 

General and Administrative Expenses

 

General and administrative expenses consisted primarily of professional services, salaries and related expenses including share-based compensation and other non-personnel related expenses, including legal expenses and directors and officers insurance costs. General and administrative expenses for the nine months ended September 30, 2026 were $4,141,000, a decrease of $60,000, or 1%, compared to general and administrative expenses of $4,201,000 for the nine months ended September 30, 2025. The decrease was primarily attributable to decrease of share-based compensation to our employees and service providers and insurance costs , partially offset by an increase of professional services and salaries and related expenses.

 

Change in fair value of contingent consideration

 

Change in fair value of contingent consideration for the nine months ended September 30, 2026 was a gain of $349,000. The gain is related to the contingent cash and equity consideration recognized in connection with the acquisition of MitoCareX in October 2025. Following the Company’s financing activities, the contingent cash consideration became fixed and payable and, following its final fair value remeasurement, was reclassified to accrued expenses. The gain reflects the combined effect of changes in the fair value of the contingent cash and equity consideration during the period, including a decrease in the fair value of the contingent equity consideration resulting from a decline in the market price of the Company’s common stock. The remaining contingent equity consideration remains contingent and continues to be measured at fair value at each reporting date.

 

Goodwill impairment

 

Goodwill impairment expenses consisted of a non-cash impairment loss of $6.3 million recognized in connection with the goodwill related to the MitoCareX reporting unit during the nine months ended September 30, 2026. The impairment loss was recognized following the Company’s interim goodwill impairment assessment performed during the first quarter of 2026, which was triggered by impairment indicators, including a sustained decline in the Company’s share price and market capitalization. Based on the assessment, the carrying amount of the MitoCareX reporting unit exceeded its estimated fair value. The impairment charge did not impact the Company’s cash flows or liquidity.

 

Depreciation and amortization

 

Depreciation and amortization for the nine months ended September 30, 2026 was $316,000, compared to no depreciation and amortization for the nine months ended September 30, 2025. The increase was attributable to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX in October 2025 as part of the purchase price allocation.

 

Financing expenses, Net

 

Financing expenses, net for the nine months ended September 30, 2026 was $1,870,000, an increase of $15,000 or 1%, compared to financing expenses, net of $1,855,000 for the nine months ended September 30, 2025. Financing expenses, net for the 2026 period reflect non-cash losses recognized during the first half of 2026 from changes in the fair value of the warrant liabilities associated with the amendment and restatement of our credit facility with L.I.A. Pure Capital Ltd. and the day-one losses recognized upon the issuance of the warrants in the June 2026 private placements, as well as higher interest expenses on outstanding loans and unfavorable foreign currency exchange differences, substantially offset by non-cash gains resulting from decreases in the fair value of such warrant liabilities during the third quarter of 2026. On September 29, 2026, we amended these warrants and, following their final remeasurement to fair value, the warrants were reclassified from liabilities to equity.

 

41

 

 

Income taxes

 

Income tax benefit for the nine months ended September 30, 2026 was $70,000. The tax benefit is primarily attributable to a reduction in deferred tax liabilities, and does not reflect taxable income generated from operations. The decrease in deferred tax liabilities was primarily related to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX, which resulted in a corresponding income tax benefit.

 

Net Loss from continuing operations

 

Net loss from continuing operations for the nine months ended September 30, 2026, was $13,581,000, compared to $4,887,000 for the nine months ended September 30, 2025, an increase of $8,694,000, or 178%. The increase in net loss from continued operations was primarily attributable to the recognition of a non-cash goodwill impairment loss, as discussed above.

 

Net gain (loss) from discontinued operations

 

Net gain from discontinued operations for the nine months ended September 30, 2026 was $851,000, compared to net loss from discontinued operations $508,000 for the nine months ended September 30, 2025 an increase of $1,359,000, or 268%. The increase was primarily attributable to the sale of the Company’s former Save Foods business through a share exchange transaction, which resulted in the elimination of the Company’s negative investment balance in such business. The net loss in the 2025 period related to the operating results of the former Save Foods business, which was classified as discontinued operations during 2025.

 

Total net loss

 

As a result of the foregoing, our total net loss for the nine months ended September 30, 2026 was $12,730,000 compared to $5,395,000 for the nine months ended September 30, 2025, an increase of $7,335,000, or 136%.

 

Liquidity and Capital Resources

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures. Since our inception through September 30, 2026, we have funded our operations, principally with the issuance of equity and debt.

 

As of September 30, 2026, we had cash and cash equivalents of $2,837,000, as compared to $6,044,000 as of September 30, 2025. As of September 30, 2026, we had a working capital of $5,679,000, as compared to $6,598,000 as of September 30, 2025. The decrease in our cash balance is mainly attributable to cash provided by financing activities offset by cash used in operations and cash used in investing activities.

 

On July 23, 2023, we entered into a standby equity purchase agreement with YA II PN, Ltd. (the “Investor”), pursuant to which the Investor agreed to purchase up to $3,500,000 of shares of our common stock for 40 months from the date of the purchase agreement at a price per share equal to 94% of the lowest volume-weighted average price (“VWAP”) of the common stock for the three days prior to the delivery of each advance notice from us, subject to certain limitations, including that the Investor cannot purchase a number of shares that would result in it beneficially owning more than 4.99% of our outstanding shares of common stock. In December 2023, we completed an investment round in the aggregate amount of $3,500,000.

 

On December 22, 2023, we entered into an additional standby equity purchase agreement with the Investor, pursuant to which the Investor has agreed to purchase up to $20 million of shares of our common stock for 36 months from the date of the purchase agreement at a price per share equal to 94% of the lowest VWAP of our common stock for the three trading days immediately following the delivery of each advance notice from us. The agreement will terminate automatically on the earlier of January 1, 2027, or when the Investor has purchased an aggregate of $20 million of our shares of common stock. We have the right to terminate the purchase agreement upon five trading days’ prior written notice to the Investor. We have sold 5,457 shares of common stock at an average purchase price of $602.45 to the Investor.

 

42

 

 

In connection with and subject to the satisfaction of certain conditions set forth in the purchase agreement, upon our request, the Investor pre-advanced to us up to $3,000,000 of the $20,000,000 commitment amount (a “Pre-Advance”), with each Pre-Advance to be evidenced by a promissory note (each, a “Note”). The Pre-Advance made to us will be subject to a 3% discount to the principal amount equal to each Note. Each Note accrues interest on the outstanding principal balance at the rate of 8% per annum. The Company is required to pay, on a monthly basis, one tenth of the outstanding principal amount of each Note, together with accrued and unpaid interest, either (i) in cash or (ii) by submitting an Advance notice pursuant to the purchase agreement and selling the Investor shares, or any combination of (i) or (ii) as determined by us. The initial repayment is due 60 days after the issuance of a Note, followed by subsequent payments due every 30 days after the previous payment. Unless otherwise agreed to by the Investor, any funds received by us pursuant to the purchase agreement for the sale of shares will first be used to satisfy any payments due under an outstanding note.

 

On May 12, 2025, we entered into an amendment to the standby equity purchase agreement with the Investor (the “Purchase Agreement Amendment”) with respect to the balance of approximately $16 million then remaining available under the standby equity purchase agreement, pursuant to which the Investor committed to advance us an aggregate principal amount of $3,000,000.

 

On August 12, 2025, pursuant to the Purchase Agreement Amendment, we issued a revised promissory note in the principal amount of $1,500,000 to the Investor.

 

As of November 16, 2026, we have sold 56,431 shares of common stock at an average purchase price of $131.85 to the Investor.

 

On October 20, 2025, upon fulfillment of all remaining closing conditions set forth in the Securities Purchase and Exchange Agreement, dated February 25, 2025, as amended on May 18, 2025 and July 23, 2025, by and among the Company, MitoCareX, SciSparc Ltd., Dr. Alon Silberman and Prof. Ciro Leonardo Pierri, and as consideration thereunder, the Company remitted a cash payment in the amount of $700,000 to SciSparc Ltd.

 

On December 10, 2024, we entered into a securities purchase agreement with certain investors for gross proceeds of approximately $1,500,000 in a private placement. The private placement closed on January 2, 2025, at which time we issued 1,392 shares of common stock, pre-funded warrants to purchase 3,711 shares of common stock and warrants to purchase 7,654 shares of common stock.

 

On October 1, 2024, we entered into a facility agreement with L.I.A. Pure Capital Ltd. On May 27, 2026, following stockholder approval, we and with L.I.A. Pure Capital Ltd. released from escrow the signatures to an amended and restated facility agreement, which increased the total amount available under the credit facility from EUR 6.0 million to EUR 10.0 million. The principal economic terms of the credit facility otherwise remained substantially unchanged. On October 7, 2026, L.I.A. Pure Capital Ltd. exercised warrants issued in connection with the amended and restated facility agreement for an aggregate cash consideration of approximately $552 thousand. The exercise related to 110,337 shares of Common Stock at an exercise price of $5.00 per share. Following the exercise, the warrant remains exercisable for 259,663 shares of Common Stock. See Note 9 for additional information.

 

On June 12, 2026, we entered into a securities purchase agreement with certain investors for the issuance of 62,379 shares of common stock in a registered direct offering and warrants to purchase 62,379 shares of common stock in a concurrent private placement. The warrants have an exercise price of $20.04 per share. The offerings closed on June 15, 2026, and generated aggregate gross proceeds of approximately $1.25 million, before offering expenses.

 

On June 22, 2026, we entered into a securities purchase agreement with certain investors for the issuance of 82,204 shares of common stock in a registered direct offering and warrants to purchase 82,204 shares of common stock in a concurrent private placement. The warrants have an exercise price of $35.28 per share. The offerings closed on June 24, 2026, and generated aggregate gross proceeds of approximately $2.9 million, before offering expenses.

 

43

 

 

The table below presents our cash flows for the periods indicated:

 

  

Nine Months Ended

September 30,

 
   2026   2025 
Net cash used in operating activities   (3,186,000)   (2,311,000)
           
Net cash used in investing activities   (3,351,000)   (1,898,000)
           
Net cash provided by financing activities   5,376,000    8,097,000 
           
Effect of exchange rate changes on cash and cash equivalents and restricted cash   24,000    (27,000)
           
Increase (decrease) in cash and cash equivalents   (1,137,000)   3,861,000 

 

Going Concern

 

Since our incorporation, we incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. As of September 30, 2026, we had an accumulated deficit of $51,253,000, and we expect to incur losses for the foreseeable future. We have financed our operations mainly through fundraising from various investors and have limited revenue from our products and therefore are dependent upon external sources to finance our operations. There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations. These factors raise substantial doubt about our ability to continue as a going concern through at least twelve months from the date of this Quarterly Report.

 

We believe that our existing capital resources will not be sufficient to support our operating plan during the twelve months following the date of issuance of these financial statements. We will likely seek to raise additional capital to support our growth or other strategic initiatives through the issuance of debt, equity, or a combination thereof. There can be no assurance we will be successful in raising additional capital on favorable terms, or at all.

 

As a result, there is substantial doubt about our ability to continue as a going concern. If we are unable to obtain sufficient amounts of additional capital, we may be required to reduce the scope of our planned development, which could harm our business, financial condition and operating results. If we obtain additional funds by selling any of our equity, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or the equity securities may have rights preferences or privileges senior to the common stock. If we issue debt securities, there may be negative covenants which may restrict our company’s activities. If adequate funds are not available to our company when needed on satisfactory terms, we may be required to cease operating or otherwise modify our business strategy. The financial statements included in this Quarterly Report do not include adjustments for measurement or presentation of assets and liabilities, which may be required should we fail to operate as a going concern.

 

Operating Activities

 

Net cash used in operating activities was $3,186,000 for the nine months ended September 30, 2026, as compared to $2,311,000 for the nine months ended September 30, 2025. The increase is mainly attributable to higher cash used to fund operating activities in the nine months ended September 30, 2026, including MitoCareX’s research and development activities. The increase was partially offset by decrease in prepaid expenses and other current assets, while a decrease in other liabilities increased cash used in operating activities.

 

44

 

 

Investing Activities

 

Net cash used in investing activities was $3,351,000 for the nine months ended September 30, 2026, as compared to net cash used in investing activities of $1,898,000 for the nine months ended September 30, 2025. The increase of $1,453,000 was primarily attributable to the investment of $3,300,000 in short-term bank deposits during the 2026 period, compared to no such investments in the corresponding 2025 period. This increase was partially offset by proceeds of $604,000 from repayments of loans related to solar photovoltaic projects, lower investments in solar projects under development and in the solar photovoltaic joint venture project, and the absence of short-term loans granted during the 2026 period, compared to $786,000 of short-term loans granted in the corresponding 2025 period. These offsetting factors were partially reduced by the purchase of property and cash outflows related to discontinued operations in the 2026 period.

 

Financing Activities

 

Net cash provided by financing activities was $5,376,000 for the nine months ended September 30, 2026, as compared to net cash provided by financing activities of $8,097,000 for the nine months ended September 30, 2025, representing a decrease of $2,721,000. During the nine months ended September 30, 2026, cash provided by financing activities primarily consisted of gross proceeds of $4,150,000 from the June 2026 private placements and net proceeds of $2,896,000 under the standby equity purchase agreement, partially offset by the repayment of a $1,200,000 promissory note and a payment of $470,000 in contingent consideration related to the MitoCareX acquisition. The decrease compared to the corresponding prior-year period was primarily attributable to the absence of proceeds from warrant exercises and promissory notes received in 2025, repayments of short-term loans in 2026, and lower net proceeds from the purchase agreement, partially offset by higher proceeds from the issuance of shares and warrants in 2026.

 

Item 3. Quantitative And Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Principal Executive Officer and our Principal Financial Officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our management, including each of our Principal Executive Officer and our Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. Based on such evaluation, each of our Principal Executive Officer and Principal Financial Officer has concluded that, as of September 30, 2026, our disclosure controls and procedures were effective.

 

Changes in Internal Control over Financial Reporting

 

During the period covered by this Quarterly Report, following the acquisition of MitoCareX, we included MitoCareX within our existing financial reporting and consolidation controls. The inclusion of MitoCareX did not result in changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

45

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially owner of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company. The Company’s property is not the subject of any pending legal proceedings.

 

Item 1A. Risk Factors.

 

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information under this item.

 

Item 2. Unregistered Sales Of Equity Securities And Use Of Proceeds

 

Except as set forth below, there were no sales of equity securities during the period covered by this Quarterly Report that were not registered under the Securities Act and were not previously reported in a Current Report on Form 8-K filed by the Company. On August 31, 2026, pursuant to the Securities Purchase and Exchange Agreement dated February 25, 2025, as amended, entered into in connection with the acquisition of MitoCareX, the Company issued an aggregate of 6,978 shares of common stock (as adjusted to give effect to the 1-for-5 reverse stock split effected on November 9, 2026) to the former shareholders of MitoCareX upon achievement of the first milestone under such agreement. The shares were issued as contingent consideration for the acquisition, without any additional cash consideration.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosure

 

Not applicable.

 

Item 5. Other Information

 

During the three months ended September 30, 2026, none of the Company’s directors or officers adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangements as defined in Item 408(a) of Regulation S-K.

 

46

 

 

Item 6. Exhibits.

 

Exhibit    
Number   Description
31.1*   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
     
31.2*   Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
     
32.1**   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2**   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
     
*   Filed herewith.
     
**   Furnished herewith.

 

47

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: November 16, 2026 NEXENTIS TECHNOLOGIES INC.
     
  By: /s/ David Palach
  Name: David Palach
  Title: Chief Executive Officer
    (Principal Executive Officer)
     
Date: November 16, 2026 By: /s/ Lital Barda
  Name: Lital Barda
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

48

Keep reading